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Robert Craig Peery 
OPTIMIZATION OF SURVIVIN DIMERIZATION INHIBITORS FOR THE 
TREATMENT OF DOCETAXEL-RESISTANT PROSTATE CANCER 
Despite therapeutic advancements, prostate cancer remains the second 
most common cause of cancer-related mortality in men. Docetaxel is the first 
cytotoxic agent to show modest improvements in overall survival rate in patients 
with metastatic prostate cancer. Unfortunately, over half of these patients do not 
respond to treatment and ultimately all develop resistance. The mechanism 
mediating docetaxel resistance remains unknown. Survivin has a classical 
biological role in cancer, in fact survivin has been shown to be overexpressed in 
almost every solid tumor and is associated with drug resistance and clinically 
aggressive disease. In these studies I demonstrate that docetaxel resistant cells 
have overexpression of survivin compared to sensitive parental cells, knockdown 
of survivin decreases docetaxel resistance, and stable overexpression of survivin 
increases resistance to docetaxel. The data in these studies suggest that survivin 
is likely implicated in docetaxel resistance and treatment with a direct survivin 
inhibitor may sensitize resistant cells to docetaxel. To this end the evaluation and 
optimization of two different backbones of survivin inhibitors was performed. One 
such inhibitor identified is LQZ-7-3 which decreases survivin level via 
proteasome degradation, leads to apoptosis of cells, and showed efficacy in a 
prostate cancer xenograft model in vivo when given in an oral formulation. LQZ-
7-3 showed strong specificity to survivin versus other IAP family members at the 
protein level. Another inhibitor, LQZ-7F-1, demonstrated nanomolar inhibition of 
  ix 
cancer cell growth and similar effects on survivin. Both compounds synergized 
with docetaxel in vitro warranting future in vivo efficacy studies as a combinatorial 
therapy. Overall, our findings indicate survivin is a significant contributor to 
docetaxel resistance in metastatic prostate cancer at the molecular level and 
survivin inhibitors may prove efficacious as a new therapy to sensitize cancer 
cells to chemotherapies.  
Travis Jerde, Ph. D., Co-Chair 
Jian-Ting Zhang, Ph. D., Co-Chair 
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CHAPTER 1. INTRODUCTION 
1.1 Prostate Cancer 
1.1.1 Prostate Biology, Statistics, Cancer Development, Natural History 
 The prostate is a male-specific, walnut-sized exocrine gland located 
between the bladder and the penis and just in front of the rectum. Biologically, 
the prostate is responsible for secreting and supplying a slightly alkaline fluid that 
make up roughly thirty percent the volume of sperm. This fluid contains a cocktail 
of proteins, minerals, and enzymes that helps nourish, protect, and escort sperm 
to fertilize an egg [1]. The prostate surrounds the urethra, a tube that runs from 
the bladder through the length of the penis which is responsible for transporting 
semen and urine out of the body [2]. The entire prostate itself is encapsulated by 
a bundle of collagen, elastin, and large amounts of smooth muscle referred to as 
the prostatic capsule [3].  
The prostate has been historically categorized as having a structure 
consisting of 4 major areas, with three unique zones that are histologically 
distinct and anatomically independent (Figure 1) [4]. These areas are defined as 
the non-glandular fibromuscular stroma that surrounds the organ, the peripheral 
zone, the transition zone, and the central zone [5]. The peripheral zone is the 
outermost zone of the prostate that is closest to the rectum. It is the largest zone 
of the prostate and is the zone that is able to be felt during a digital rectal 
examination. This is the zone of origin for 70-80% of all prostate cancer tumors 
[6]. The transition zone surrounds the prostatic urethra and comprises about 20% 
of the gland until the age of 40, in which it begins to swell and impinge on the 
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urethra in a condition referred to as Benign Prostatic Hyperplasia (BPH). The 
transition zone is the place of origin for 10-20% of tumors [7]. The final zone of 
the prostate, the central zone, is a very rare location for tumor development with 
~2.5% of cancers arising in this zone. However, these central zone cancers tend 
to be highly aggressive and more invasive [8]. The androgen receptor (AR) 
signaling pathway is the critical regulator of prostate development and 
homeostasis [9].  
 Histologically, the prostate is tubulo-alveolar gland with two major generic 
cell types: stromal and epithelial. The stromal compartment of the prostate 
contains a multitude of different cell types, but the most abundant cells are 
smooth muscle cells and fibroblasts. The pseudostratified epithelium contains 
three differentiated epithelial cell types: luminal, basal, and neuroendocrine [10]. 
The luminal epithelium cells form a continuous layer of polarized columnar cells 
that produce important secretory factors and proteins and express high levels of 
androgen receptor [11]. Underneath the luminal layer, is a basal layer of cuboidal 
epithelial cells that are not secretory and are involved in replenishing the prostate 
tissue [12]. The separation of the stromal and epithelial compartments is formed 
by a large basement membrane consisting of extracellular matrix proteins. 
  
  3 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic of the human prostate anatomy. The prostate is 
classically subdivided in to three zones. The peripheral zone is the largest 
zone of the prostate. The transition zone is the part of the prostate that 
surrounds the urethra. The central zone lies around the ejaculatory ducts 
and is a rare place for tumor development, however these cancers are 
typically highly aggressive in nature. 
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Prostate cancer is defined as the malignant, uncontrolled growth of cells 
within the prostate gland. Prostate cancer is the most common non-cutaneous 
cancer diagnosed in men with about 1 in 6 diagnosed with prostate cancer in 
their lifetime.  Annually, there are approximately 175,000 new incidences of 
prostate cancer in the Unites States alone. About 1 in 41 men will die of prostate 
cancer and there are roughly 32,000 prostate cancer related deaths in the United 
States each year [13]. The vast majority of prostate cancers are classified as 
adenocarcinomas of the epithelial gland cells in the lumen of the prostate. 
 The exact cause of prostate cancer remains unknown, however there 
exists several factors that have been linked to an increase risk for the 
development of prostate cancer. The number one risk factor for prostate cancer 
is advanced age, with 6 in 10 incidences of prostate cancer diagnosed in men 
over 65. Familial history or African American ancestry are all risk factors 
associated with increased propensity to develop prostate cancer [14]. The 
presence of chronic inflammation in the prostate caused by a multitude of 
different factors such as environmental exposures, dietary factors, hormonal 
changes, or infections has also been linked prostate cancer development [15]. 
The presence of chronic inflammation may lead to cellular damage that increases 
the rate of mutation and transition of a normal cell to a cancer cell. A limited 
number of prostate cancers, roughly 5%, result from inherited mutations in genes 
that are involved in functions like DNA repair (BRCA2). 
 Although the exact pathway of prostate cancer progression remains under 
debate, there is classically considered to be three main stages: initiation, 
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progression, and metastasis (Figure 2). The initiation step involves the loss of 
basal cells and the expansion of luminal cells in to the duct to form a hyperplastic 
lesion referred to as Prostatic Intraepithelial Neoplasia (PIN) [16]. While not 
conclusive, it is often considered that PIN represents a precursor to prostate 
cancer. This step has been linked to cellular processes such as chronic 
inflammation, oxidative or DNA damage, and telomere shortening. Certain 
genetic factors have also been associated with this stage such as Myc oncogene 
overexpression [17] and NKX3.1 prostate specific tumor suppressor, a negative 
regulator or epithelial growth, down-regulation [18]. Phosphatase and Tensin 
Homolog (PTEN) is a negative regulator of PI3k/Akt pathway and is frequently 
deleted tumor suppressor in prostate cancer with monoallelic loss in 60% of 
prostate cancers. Complete loss of PTEN is associated with castration resistance 
and metastasis [19]. The most common molecular subtype of prostate 
TMPRSS2:ERG gene fusion is seen in approximately half of prostate cancer 
patients [20]. ERG overexpression contributes to the development of castration 
resistance through the disruption of AR signaling [21]. 
The transition to progression stages and adenocarcinoma, involves 
continual expansion of the luminal cells in to the duct which typically is 
associated with re-activation of developmental signaling pathways like 
ERK/MAPK [22]. Eventually the cells expand completely out of the duct, develop 
castration-resistance characterized by lack of response to androgen ablation, 
and undergo metastasis after Epithelial to Mesenchymal transition. Dysregulation 
of EZH2 a histone methyltransferase that acts to silence many tumor suppressor 
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genes that limit prostate cell growth and proliferation is often associated with this 
process [23].    
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Figure 2. Progression pathway for the human prostate cancer 
development. The development of prostate cancer can crudely be 
defined in to the 3 sections: initiation, progression, and treatment stages. 
These stages of progression are highlighted above as well as the 
molecular processes that have been linked with playing a critical role in 
each stage. Each stage of progression involves the loss of some 
architecture of the normal epithelium leading to the eventual 
development of full blown metastatic prostate cancer. Adapted from 
Abate-Shen and Shen (2000). 
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The Gleason scoring system is a grading system that is used to calculate 
aggressiveness of prostate cancers. This system is a critical component for 
helping physicians choose suitable treatment options for individual patients 
based on the characteristics of the tumor. The Gleason scoring system involves 
a range from 1-5: 1 representing small, uniform glands, 2 representing more 
space, stroma between glands, 3 representing distinct infiltration of cells at gland 
margins, 4 representing irregular masses of neoplastic cells with few glands, and 
5 describing poorly differentiated abnormal tissue. When a Gleason score is 
given to a patient two scores are provided to account for the fact that most 
prostate cancers are made up of cells that would fall in distinctive grades. The 
first score is considered the primary score and represents the score for the 
largest section of the tumor. The next largest area of the tumor is used to provide 
the secondary score. The summation of these two scores determines the 
Gleason score [24, 25].  
A score of 6 or less in the Gleason system describes cancer cells that 
more closely resemble normal cells, are generally slow growing, and tend to 
remain localized. A score of 7 generally provides the patient with the idea that 
they are at a medium risk for aggressive cancer that depends on the breakdown 
of the scoring. If a tumor is given a score of 3+4 it is likely to remain in the 
prostate and have a more favorable outlook. A tumor with a score of 4+3 tend to 
be more aggressive and have an increased likelihood of spreading and further 
growth. In fact 4+3 cancers have been shown to have a 3 fold increase in 
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lethality over 3+4 cancers [26]. Anything that scores over 8 is considered to be a 
high-grade tumor that is likely highly aggressive and will spread quickly.  
The gleason score is utilized to calculate the grade group for prostate 
cancer patients. Grade group 1 is a Gleason score of 6 or less and grade group  
2 or 3 is a Gleason score of 7. Grade group 4 is a Gleason score of 8 and grade 
group 5 is a Gleason score of 9 or 10. The grade group and prostate specific 
antigen level test are used to stage the prostate cancer. The stage of the 
prostate cancer will dictate the treatment guidelines that will be followed clinically.  
There are four unique stages in prostate cancer: Stage I, Stage II, Stage 
III, and Stage IV. Stage I prostate cancer is found only in the prostate. The 
cancer can be discovered by needle biopsy during tissue removal surgery. Stage 
I cancer may also be detected by digital rectal exam and found in one-half or less 
of one side of the prostate. Stage I prostate cancer is classified as grade group 1 
and PSA level less than 10. Stage II can be subdivided into IIA, IIB, and IIC but 
the prostate cancer is still contained within the prostate. Stage IIA prostate 
cancers are grade group 1 and have PSA level of at least 10 but less than 20. 
Stage IIB are grade group 2 with a PSA level of less than 20 and the prostate 
cancer is in one or both sides of the prostate. Stage IIC prostate cancers are 
grade group 3 or 4 and PSA level less than 20. Stage III prostate cancer can be 
subdivided into IIIA, IIIB, and IIIC. Stage IIIA the PSA level is at least 20 and 
grade group 1, 2, 3, or 4. Stage IIIB the cancer has spread to seminal vesicles or 
nearby tissues or organs, the PSA can be any level, and grade group 1, 2, 3, or 
4. Stage IIIC the PSA can be any level and the grade group is 5. Stage IV can be 
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subdivided into IVA and IVB. Stage IVA the prostate cancer has spread to local 
tissues and nearby lymph nodes and is grade group 1, 2, 3, 4, or 5. Stage IVB 
the cancer has spread to other parts of the body such as bones or distant lymph 
nodes [27]. 
 
1.1.2 Current Treatment Options 
The treatment roadmap for patients with prostate cancer depends on the 
stage of the prostate cancer and the sequential progression of treatment options 
is highlighted in Figure 3. Standard treatment of stage I involves the use of 
active surveillance or watchful waiting [28]. This stage may also include 
treatment options such as high-intensity ultrasounds, radiation therapy, or 
radiopharmaceutical therapy to ablate the prostate cancer cells [29]. Patients 
whom previous treatments are unsuccessful or have a high risk of progression, 
often times radical prostatectomy to completely remove the prostate is performed 
followed by radiation therapy [30]. 
Stage II prostate cancer treatment plan may also include watchful waiting 
and active surveillance, however if the cancer begins to grow hormone therapy is 
often given. Similar to stage I, radical prostatectomy or internal therapy radiation 
may be necessary for stage II. Stage III prostate cancer treatment involves 
external radiation therapy with subsequent hormone therapy. The standard of 
care for stage IV prostate cancer is hormone therapy with or without 
chemotherapy.  
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  Often times the above treatment regimen is successful and contributes 
greatly to the nearly 99% survival rate for prostate cancer patients, however, for 
patients with recurrent or metastatic castration resistant prostate cancer 
(mCRPC) androgen deprivation therapy (ADT) is the standard of care followed 
by chemotherapy if necessary. Since androgens and androgen signaling are the 
main contributor to prostate growth and homeostasis which becomes 
exacerbated during prostate cancer progression, androgen deprivation therapy’s 
goal is to reduce the androgen receptor activity and level of androgens. ADT can 
be accomplished by physical or chemical castration, the use of androgen 
receptor antagonists, or luteinizing-hormone release agonists [31]. Biological 
therapy with sipuleucel-T may be an option for patients already treated with ADT. 
More recently, there has been expanding interesting data that suggest the 
familiar standard of care chemotherapeutic for metastatic disease, docetaxel may 
be a significant option for patients with hormone-sensitive or earlier stage 
prostate cancer. For a long-time, docetaxel has been not used in this context 
because of potential toxicities associated with its use that have been deemed 
unnecessary to put this population of patients through. Therefore, docetaxel has 
been saved for patients with metastatic disease that have high tumor burden. 
However, in multiple studies docetaxel has proven beneficial in conjunction with 
ADT for localized prostate cancers. In the CHAARTED and STAMPEDE trials the 
addition of rounds of docetaxel improved overall survival of prostate cancer 
patients [32]. Lately, updated results from another study, GETUG-12, has 
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demonstrated that the addition of four rounds of docetaxel reduces the risk of 
relapse or death in men with high-risk localized disease [33].  
 
1.1.2.1 After Androgen Deprivation Therapy 
Unfortunately, for many patients ADT fails and the cancer becomes 
castration resistant. In such cases, chemotherapies like the aforementioned 
docetaxel and cabazitaxel are used as the standards of care for treatment of 
metastatic cancers and have been shown to improve patient survival [31]. 
Paclitaxel is not implicated for use in prostate cancer because of the dose-
limiting toxicity peripheral neuropathy [34]. However, in the context of prostate 
cancer nearly 50% of all patients do not respond to taxanes and ultimately all 
develop resistance [35]. Hence, there still exists a tremendous need for new 
targets and drugs to sensitize these resistant cancers to current standard of care 
treatments.  
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Figure 3. Progression of treatments given to prostate cancer 
patients. Curved red line represents increasing PSA level over time. In 
prostate cancer localized to the prostate, local therapy is applied which 
includes surveillance, waiting, or surgery. After progression of the 
cancer, androgen deprivation therapy is used to deplete the cancer 
cells of androgens required for growth and proliferation. If the prostate 
cancer progresses to a castration-resistant metastatic form, taxane 
chemotherapies are given to patients.  
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1.2 Docetaxel Resistance Mechanisms 
Docetaxel, a taxane chemotherapeutic, has been a mainstay treatment for 
men with metastatic prostate cancer since 2004 and is still considered the 
standard of care for patients with late stage disease [36]. Docetaxel exerts its 
function by poisoning the mitotic spindle apparatus by binding beta-tubulin in 
microtubules, stabilizing the microtubule structures and preventing their dynamic 
polymerization and depolymerization [37]. As mentioned before docetaxel has 
been plagued by the fact that half of mCRPC patients do not respond to 
docetaxel and ultimately all patients develop resistance. The development of 
docetaxel resistance has been the limiting factor contributing to docetaxel only 
increasing overall patient survival 3 months over previous treatment regimens 
[38].  
 
1.2.1 Proposed Mechanisms 
There exists a multitude of docetaxel resistance mechanisms that have 
been reported that allow prostate cancer cells to escape the mitotic arrest 
induced by docetaxel treatment. The first identified mechanism is the 
overexpression of multi-drug resistance genes in prostate cancer. Specifically, 
MDR1/ABCB1 gene codes for the p-glycoprotein (P-gp) drug efflux pump which 
extrudes docetaxel from the cell and prevents its cytoplasmic accumulation [39]. 
Interestingly, P-gp expression is correlated with higher tumor grade and stage as 
well as increased prostate specific antigen (PSA) levels [40]. Alterations in 
tubulin expression have also been associated with docetaxel resistance in 
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prostate cancer. Elevated expression of bIII-tubulin has been demonstrated to 
lead to taxane resistance because of microtubules containing bIII-tubulin are less 
stable and have aberrant dynamicity that reduces the effectiveness of docetaxel 
to exert its mechanism of action [41]. Finally, defects in apoptotic pathway 
signaling and regulation have been increasingly implicated as a potential 
mechanism for docetaxel resistance. One such defect that is of particular interest 
to our lab is the overexpression of Inhibitor of Apoptosis Protein (IAP) Family 
members, particularly survivin, which leads to an imbalance of anti-apoptotic 
proteins to pro-apoptotic proteins resulting in chemoresistance and cancer 
progression [42]. As docetaxel exerts its cytotoxic effects by disrupting 
microtubule dynamics and promoting apoptosis through cell cycle arrest, survivin 
as a key molecular player in both processes is likely a critical component of the 
docetaxel resistant phenotype. Thus, targeting survivin may be a viable strategy 
for sensitizing resistant prostate cancer cells to docetaxel.  
 
1.3 Survivin and IAP Family 
1.3.1 IAP Protein Family 
 The IAP family members are historically described as the major regulators 
of the apoptosis pathway because of their ability to inhibit the cysteine proteases, 
caspases [43]. Recently, IAPs have become of increasing interest as potential 
biomarkers and therapeutic targets in cancer due to their dysregulation and 
overexpression being associated with poor clinical outcomes and chemotherapy 
resistance [44]. The IAP family consists of eight unique members: Neuronal 
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Apoptosis Inhibitory Protein (BIRC1), Cellular Inhibitor of Apoptosis Protein 1 
(BIRC2), Cellular Inhibitor of Apoptosis Protein 2 (BIRC3), X-linked Inhibitor of 
Apoptosis Protein (BIRC4), Survivin (BIRC5), BIR Repeat-Containing Ubiquitin 
Conjugating Enzyme (BIRC6), Livin (BIRC7), and IAP-like Protein 2 (BIRC8) 
(Table 1). Each member of the family is characterized by the existence of 1 to 3 
Baculovirus IAP Repeat (BIR) domains and the majority of the proteins also 
contain a carboxyl-terminal RING domain [45]. CIAP-1 and CIAP-2 are the only 
members that possess a caspase recruitment domain [46]. Although all members 
of the family contain a BIR domain thought to be necessary for binding caspases, 
XIAP is the only IAP protein shown to physically associate with caspases directly 
and inhibit their activity [47]. XIAP also contains an E3 ligase domain capable of 
ubiquitination of caspases to promote their degradation and inactivation [48].  
 
1.3.2 Apoptosis Pathway 
 As mentioned, the IAP proteins are critical regulators of the intrinsic and 
extrinsic programmed cell death pathways. In the intrinsic apoptosis pathway, 
non-receptor mediated stimuli that negatively affect the cell such as growth factor 
withdrawal, hypoxia, or DNA damage is detected by the cell [49]. These stimuli 
result in changes to the inner mitochondrial membrane that lead to the opening of 
the mitochondrial permeability transition pore and the subsequent release of pro-
apoptotic proteins cytochrome c and Smac/DIABLO [50]. Cytochrome c binds to 
Apaf-1, activates it, and complexes with pro-caspase 9 to form what is known as 
the apoptosome [51]. The apoptosome activates caspase 9 which cleaves and 
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activates caspase 3 to start the execution pathway. Smac/DIABLO is known to 
bind and suppress the activity of IAP family members [52].  
 The extrinsic pathway involves receptor-mediated interactions at the cell 
membrane involving death ligands such as TNF-a, Fas ligand, or Targeting TNF-
related apoptosis-inducing ligand (TRAIL) [53, 54]. Upon binding of a death 
ligand to a death receptor, the receptors oligomerize bringing their death 
domains in contact which results in the recruitment of specialized adaptor 
proteins. These adaptors provide the requisite scaffolding for procaspase 8 
binding to form the death inducing signaling complex (DISC) [55]. Activated 
caspase 8 can then cleave caspase 3 to begin the execution pathway. C-FLIP is 
a master anti-apoptotic regulator that can be recruited to the DISC complex and 
inhibit caspase 8 activation [56]. The extrinsic pathway connects to the intrinsic 
pathway through the cleaving of a protein BID to t-BID, which translocate to the 
mitochondria to promote outer mitochondrial membrane permeabilization [57].  
 
1.3.3 Survivin Structure and Function 
Survivin (also called BIRC5) represents the smallest member of the IAP 
family with a molecular weight of 16.5 kDa [58]. Survivin consists of 142 amino 
acid residues with a single zinc finger fold Baculovirus Repeat (BIR) domain, a 
dimerization domain at two different locations in the linear sequence, and a C-
terminal domain for protein-protein interaction and nuclear export (Figure 4A 
and 4B). Survivin exists as a stable bow-tie-shaped homo-dimer (Figure 4C) 
formed through interactions of the N-terminal region, linker region, and the N- 
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terminus of alpha helix four [59]. The homo-dimeric interface is mostly 
hydrophobic with greater than 75% of the residues being nonpolar [60]. The 
buried accessible area in the interface of a monomeric survivin is 550 Å2 and 
occupies only 6% of the total accessible area of a monomer (9,044 Å
2
) compared 
with ~20% in most other dimeric or oligomeric proteins [61].  
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Table 1. Members of the IAP family. 
IAP Member Abbreviation Mol. Wt. Reference 
Neuronal apoptosis inhibitory 
protein 
NAIP/BIRC1 160 kDa [62] 
Cellular Inhibitor of Apoptosis 
protein 1 
c-IAP1/BIRC2 69 kDa [63] 
Cellular Inhibitor of Apoptosis 
protein 2 
c-IAP2/BIRC3 68 kDa [63] 
X-linked Inhibitor of Apoptosis 
protein 
XIAP/BIRC4 55 kDa [64] 
Survivin Survivin/BIRC5 16.5 
kDa 
[65] 
BIR-repeat-containing 
ubiquitin conjugating enzyme 
BRUCE/BIRC6 528 kDa [66] 
Melanoma IAP/Livin ML-
IAP/livin/BIRC7 
33 kDa [67] 
IAP-like protein 2 ILP2/BIRC8 27 kDa [68] 
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Figure 4. Structure of survivin.  A. Schematic linear structure of 
survivin with domains highlighted in different colors. DD, dimerization 
domain; BIR, Baculovirus Repeat domain; PBD, protein-binding domain; 
NE, nuclear export. B. Atomic structure of survivin (PDB 1F3H) with 
domains color in correspondence with that shown in the linear structure 
in panel A. The zinc finger residues (Cys57, Cys60, His77, and Cys84) are 
shown in ball and stick symbols with the zinc ion shown as a red ball. C. 
Atomic structure of dimeric survivin (PDB 1F3H) with one subunit shown 
in pink and the other in blue. From Peery and Zhang (2017). 
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Ectopic over-expression of survivin inhibits both extrinsic and intrinsic 
apoptosis pathways in cell lines and animal models [69-72]. Survivin’s 
mechanism of inhibition of apoptosis remains elusive, however several 
possibilities have been proposed (Figure 5). Survivin has been suggested to 
directly bind to and inhibit caspase 3 and 7 while contradictory evidence exists 
that bring this observation under scrutiny [73, 74]. Although myc-tagged survivin 
in HEK293 cells co-immunoprecipitated with active caspase 3 and 7, survivin 
seemingly lacks the additional structural moieties such as the BIR2 domain that 
have been demonstrated to be necessary for caspase 3 and 7 binding by other 
IAP family members [75, 76]. It has also been suggested that survivin can bind to 
caspase 9 and inhibit its activation [77]. However, it was shown later using 
purified proteins that survivin alone does not bind to caspase 9 and it may require 
the presence of hepatitis B X-interacting protein (HBXIP) to bind to and inhibit 
caspase 9. The interaction between survivin and HBXIP may be responsible for 
binding to pro-caspase 9 to prevent its recruitment to the apoptosome and, thus, 
inhibit its activation [78]. It has also been postulated that an IAP-IAP complex 
between survivin and X-linked IAP (XIAP) may form to stabilize XIAP and lead to 
inhibition of caspase 9 [79]. Finally, survivin may prevent the induction of 
apoptosis by interaction with intermediate apoptotic proteins to indirectly halt 
caspase activation. SMAC/DIABLO is a proapoptotic protein that promotes 
cytochrome c dependent apoptosis by binding and antagonizing IAPs [80]. 
Survivin can bind SMAC/DIABLO and prevent SMAC/DIABLO inhibition of 
caspases [81]. Survivin has been shown to co-localize with SMAC/DIABLO and 
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disruption of their physical association induces apoptosis [82]. Thus, it is possible 
that survivin inhibits apoptosis via interaction with multiple proteins in the 
apoptosis pathway. 
In addition to the inhibition of apoptosis, survivin acts as a key mitotic 
regulator (Figure 5) and is essential for proper completion of mitosis and cell 
division [83]. Survivin expression is tightly regulated during cell cycle 
progression, peaking in the G2/M phase [84]. During mitosis, survivin localizes 
and interacts with microtubules to regulate microtubule formation during cell 
division by altering microtubule dynamics and nucleation [85]. Additionally, 
survivin is a critical component of the chromosomal passenger complex (CPC) 
that also consists of INCENP, Borealis, and Aurora B Kinase [86]. INCENP acts 
as a scaffold to stabilize the entire complex, while Borealis promotes the 
attachment of survivin to the complex [87]. Survivin appears to function in 
targeting of the CPC to the centromere and midbody during mitosis. The CPC is 
a critical regulator of several mitotic events [88] and, when localized to the 
midbody, it facilitates proper chromosome alignment during metaphase [89]. The 
CPC is also vital for correction of chromosome-microtubule attachment errors 
[90] and activation of the spindle assembly checkpoint [91].  
It has also been suggested survivin may be functioning to promote tumor 
progression via angiogenesis and metastasis. By an incomplete mechanism, 
survivin appears to upregulate Vascular Endothelial Growth Factor (VEGF) in 
endothelial cells to promote their proliferation. It is likely this involves positive cell 
signaling via the PI3K/Akt pathway to enhance B-catenin dependent transcription 
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of VEGF [92]. In the context of cancers such as glioma and breast, knocking 
down survivin decreases angiogenesis [93, 94]. There is growing evidence that 
survivin may contribute to metastasis of cancer cells via coordination with 
another Inhibitor of Apoptosis member, XIAP. In a mouse breast cancer model, 
survivin and XIAP worked in conjunction to promote cell invasion and metastatic 
dissemination. The promotion of these aggressive cancer trademarks appears to 
likely be caused by an increase in NF-kB and cell motility kinases activation [95]. 
Finally, survivin overexpression has been associated with increased metastasis 
in patient studies of colorectal and prostate cancers [96, 97]. As more research 
follows, it is becoming clearer that survivin has an ever-expanding role outside of 
its classical inhibition of apoptosis that contributes to other classical hallmarks of 
cancer. 
 
1.3.4 Survivin Regulation 
The regulation of the survivin gene is highly dynamic and involves key 
players in cell survival, cell proliferation, and developmental signaling pathways. 
At the transcriptional level, survivin is negatively regulated by several tumor 
suppressor genes such as PTEN [98] and p53 [99]. In normal cells, the p53 
target protein p21 is primarily responsible for maintenance of the low survivin 
expression pattern [100]. Notch 2 signaling has also been shown to suppress 
survivin transcription [101].  Egr-1 and KLF4 transcription factors are capable of 
binding survivin promoter and repressing its expression [102, 103]. Finally, in 
prostate epithelial cells TGF-b has been shown to downregulate survivin 
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expression via a Smad2/3 hypophosphorylation of Rb protein dependent 
pathway [104]. Deregulation of these negative regulators and their signaling 
pathways may result in the overexpression of survivin seen in most solid 
cancers.   
Survivin expression is positively regulated by several pro-oncogenic 
transcription factors which contain putative binding sites in the survivin promoter, 
such as STAT3, Sp1, NF-kB, and E2F1 [105]. The most important of these 
transcription factors in relation to survivin expression appears to be specific 
protein 1 (Sp1). In the survivin proximal promoter, there are several G/C rich Sp-
binding sites and two have been identified as being essential for sustaining basal 
survivin levels [106]. Wnt/b-catenin signaling is known to upregulate survivin 
expression in colorectal and melanoma cancer cells [107, 108]. In breast cancer, 
Stat3 has been demonstrated to be a critical driver of survivin transcription [109]. 
In liver hepatocytes, survivin is regulated by NF-kB signaling [110]. Finally, in 
prostate cancer cells the androgen receptor upregulates survivin expression 
[111].  
Survivin undergoes several post-translational modifications that are 
important for the regulation of its expression and its activities in the cell. During 
mitosis, cell division cycle protein 2 (Cdc2) phosphorylates survivin at threonine 
34, which increases the stability of survivin by reducing its proteasomal 
degradation. This phosphorylation event may also be important for survivin’s 
physical interaction with XIAP, as Threonine 34 lies within the single BIR domain 
of survivin [112]. Thus, this modification may boost its cytoprotective effect in 
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cancer cells as well. Survivin phosphorylation at threonine 117 by Aurora-B 
kinase is critical for survivin’s localization to chromosomes and microtubules 
during mitosis [113]. Protein kinase A phosphorylation of survivin at serine 20 
interferes with survivin’s binding to XIAP and diminishes its anti-apoptotic role in 
the cell [114]. CREB-binding protein acetylation of survivin on lysine 129 is 
critical for the nuclear localization of survivin. Deacetylation at this site is 
responsible for the accumulation of survivin monomers that complex with CRM1 
nuclear export protein to shuttle survivin out of the nucleus [115]. Overall, the 
dynamic status of these post-translational modifications of survivin are crucial in 
promoting survivin’s functional roles and its localization in the cell. 
The bifunctionality of survivin can be attributed to its subcellular 
distribution to different pools in the cell. Survivin has classically been 
demonstrated to exist in pools in the cytoplasm, nucleus, and mitochondria. The 
respective distribution of survivin into each of these separate pools appears to be 
cell type specific. In the mitochondrial and cytoplasmic pools, survivin acts in its 
anti-apoptotic capacity where it complexes with other IAPs to inhibit caspase 
activation and activity. As previously mentioned, in the nuclear pool survivin acts 
in the CPC to position and align chromosomes during mitosis.  
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Figure 5. Participation of survivin in regulating apoptosis and cell 
cycle progression. Survivin regulates cell cycle progression by binding 
to the chromosomal passenger complex in the nucleus and helping to 
orient and align chromosomes during metaphase. Survivin also regulates 
apoptosis by binding to and inhibiting SMAC/DIABLO and complexing 
with other proteins like XIAP and HBXIP to prevent caspase activity and 
the eventual caspase cascade execution pathway of apoptosis. From 
Peery and Zhang (2017). 
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1.4 Drug Discovery Cycle  
The process of drug discovery and development is long, arduous, and 
expensive process with many cyclical iterations. The general overview of the 
drug discovery cycle is highlighted in Figure 6. The process begins with the 
identification of a druggable biological target with an implication in human 
disease followed by the development of assays to assess the in vitro activity of 
the target. The next step is an iterative cyclical process that begins with the 
screening of libraries of compounds. This is followed by in vitro high throughput 
screening and cell-based assays to identify compounds and cells response to 
them. Many times this is often accompanied with secondary screening of 
promising candidates in vivo for assessment of bioavailability, safety, and 
efficacy. This cyclical process eventually yields a primary hit for future analysis. 
The compound hit is then typically utilized in structure activity relationship (SAR) 
assays to synthesize analogues. The analogues are tested in cell-based assays 
to develop a primary lead. The final steps of the drug discovery process involves 
another round of iterative cyclical steps in which optimized leads are tested in 
vivo for efficacy, safety, and pharmacodynamics and pharmacokinetics 
properties. After many repeated cycles of this process, the goal is to have 
established a candidate drug with a strong safety profile for clinical development. 
At this stage the goal is to have a portfolio for this compound ready to be 
approved for Phase I clinical trials [116]. 
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Figure 6. Drug Discovery Cycle. The development of small molecule 
inhibitors is a long cyclical process that involves identification of a biological 
target and screening of large libraries of compounds. After rounds of 
characterization assays, an initial hit is taken to structure activity 
relationship analyses. A lead compound is identified and goes through a 
series of in vivo optimization assays before a portfolio is built for candidate 
drug development in Phase 1 clinical trials. Adapted from Cohrt (2018). 
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1.5 Survivin as a Target for Drug Discovery  
For over a decade, survivin has drawn a considerable attention as a potential 
novel cancer target in a variety of human cancers. The attractiveness of survivin 
as a potential cancer drug target has been in large part due to its dramatic 
dysregulation of expression between normal adult tissue and most cancers. 
Survivin is expressed to a high extent in fetal tissues [117], but is undetectable in 
most normal adult tissues [118]. Interestingly, survivin is overexpressed in almost 
all human cancers including cancers of lung, breast, colon, stomach, esophagus, 
pancreas, prostate, liver, and ovary [119]. Survivin has been consistently 
demonstrated to be an important contributor to both radiotherapy [120] and 
chemotherapy resistance [121, 122]. High level of survivin expression is 
predictive of poor clinical outcome [123] and correlates with tumor relapse [124]. 
Expressing recombinant dominant negative survivin Thr34A prevented its 
association with XIAP and caspase 9 and produced pro-apoptotic and anti-
proliferative effects on human cancer cells and suppressed tumor growth in vivo 
[125-127]. Cleavage of survivin mRNA by ribozyme increased cell death by 
caspase dependent apoptosis [128]. Down regulation of survivin expression by 
antisense oligonucleotides [129] and siRNAs inhibited cancer cell proliferation 
and increased chemosensitivity [130]. These studies using molecular probes 
along with the expression profile of survivin in cancer have established survivin 
as a target for anticancer drug discovery. Survivin’s dual role in cancer cell 
survival as well as its contribution to cancer hallmarks angiogenesis and 
metastasis also serve to highlight its attractiveness as an anti-cancer agent [131]. 
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1.5.1 Therapeutics Targeting Survivin 
Despite the promise and interest in survivin as a target for anticancer drug 
discovery, there presently exists a small portfolio of anti-survivin agents, which 
can generally be classified in to three broad categories of inhibitors targeting (1) 
regulators of survivin expression, (2) survivin interaction with ligand proteins, and 
(3) survivin homo-dimerization. In addition, survivin has also been considered 
and tested as a cancer vaccine for immunotherapy.  
 
1.5.1.1 Inhibitors Targeting Survivin Expression  
Since survivin has no known enzymatic activities and it is considered 
“undruggable”, the initial effort of targeting survivin was not on the survivin 
protein itself, but rather on inhibiting survivin expression to avoid targeting 
survivin protein directly. This approach includes the use of antisense 
oligonucleotides and small molecule inhibitors.  
 
1.5.1.1A Antisense Oligonucleotides 
Antisense oligonucleotides such as LY2181308 and SPC3042/EZN-3042 
(Table 2) have been developed to inhibit survivin expression as anticancer 
therapeutics. These oligonucleotides have been tested in clinical studies with 
mixed findings. LY2181308 is a 2’-O-methoxymethyl-modified single strand 
antisense oligonucleotide targeting survivin mRNA to limit survivin expression 
developed by Eli Lilly [132]. LY2181308 inhibited the expression of survivin gene 
at both mRNA and protein levels in a panel of cell lines and it significantly 
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inhibited growth of human tumor xenografts [133]. The positive pre-clinical 
activity of LY2181308 led to its clinical testing as a single agent and in 
combination with other chemotherapeutics. However, the outcome of these 
clinical studies are mixed. LY2181308 was well tolerated as a single agent and 
did not appear to cause additional toxicity to cytarabine and idarubicin in 
refractory or relapsed Acute Myeloid Leukemia patients [134]. With this cohort of 
16 AML patients, it appeared that the combination of LY218308 with cytarabine 
and idarubicin showed added benefits. LY218308 also inhibited survivin 
expression in patients with high survivin level although the correlation between 
survivin inhibition and response was not studied. It is also noteworthy that the 
cohort size in this study was small and a bigger cohort size is needed to validate 
the findings on added benefits.  
The findings from clinical study of LY218308 on solid tumors are not 
encouraging. Neither the phase I trial of LY218308 as a single agent for solid 
tumors [135] or in combination with docetaxel/prednisone in a phase II trial for 
castration-resistant prostate cancers [136] showed any benefit of LY2181308. 
The authors noted that lack of response might be due to the lack of survivin 
inhibition by LY2181308 in these solid tumors although survivin expression was 
not measured in these studies and they were unable to achieve pharmacokinetic 
levels necessary for survivin inhibition required. SPC3042 is a locked antisense 
oligonucleotide that targets the stop codon of the open reading frame in exon 4 of 
the survivin transcript and was under preclinical development by Santaris 
Pharma [137]. SPC3042 displayed improved potency as compared to 
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LY2181308. However, unlike LY2181308, SPC3042 had a significant effect also 
on the mRNA and protein levels of Bcl-2 in addition to that of survivin. Down 
regulation of survivin expression by SPC3042 sensitized PC-3 prostate cancer 
xenograft to taxol treatment in vivo. In 2006, Santaris Pharmaceuticals licensed 
the developmental rights of SPC3042 to Enzon-Pharmaceuticals and it was 
rebranded as EZN- 3042. In primary Acute Lymphoblastic Leukemia cells, EZN-
3042 synergized with chemotherapy and eliminated ALL cells in vitro [138]. EZN-
3042 also demonstrated success in vivo as it achieved ~60% down regulation of 
survivin mRNA in Calu-6 lung xenografts and ~40% tumor growth inhibition. In 
combination with paclitaxel, EZN-3042 achieved >80% tumor growth inhibition 
[139]. However, the phase I trial of EZN-3042 was terminated since EZN-3042 
produced several dose-limiting toxicities and it was unable to be safely 
administered with other chemotherapeutics [140]. As such, further clinical 
development of this oligonucleotide has been halted by Enzon Pharmaceuticals.  
In summary, the success in clinical trials has been limited by targeting 
survivin expression using antisense oligonucleotides, particularly for solid tumors. 
The lack of response in solid tumors suggests that this strategy may have limited 
potential in treating the difficult-to-treat and aggressive solid tumors. One 
contributing factor to the ineffectiveness of antisense oligonucleotides may be the 
intrinsic disadvantages of oligonucleotides including stability and availability 
issues. These disadvantages may also account for the dose limiting toxicities that 
have been evident in previous trials and the currently limited portfolio of FDA-
approved antisense oligonucleotide therapeutics.  
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Table 2. Antisense oligonucleotides suppressing survivin expression. 
Name Sequence Remark Reference 
LY2181
308 
5'-
TGTGCTATTCTGTGAA
TT-3' 
In-vitro IC50 of 10-100 
nM in inhibiting survivin 
expression. 
 
Lack of efficacy in phase 
II trials as a single agent 
or in combination with 
docetaxel 
 
[132], 
[133], 
[134], 
[135], 
[136] 
EZN-
3042 
5'-CTCAatccatggCAGc-
3' 
In-vitro IC50 of 5 nM in 
inhibiting survivin 
expression and IC50 of 
5-40 µM in cell killing. 
 
Phase I trial terminated 
due to dose-limiting 
toxicities 
[138], 
[139], 
[140] 
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1.5.1.1B Small Molecule Inhibitors 
In addition to antisense oligonucleotides, small molecule inhibitors (Table 
3) have also been developed by targeting transcription of the survivin gene. 
These inhibitors include YM155 and EM-1421, which have been tested in clinical 
studies, and other compounds such as SF002-96-1 and FL118, which are still at 
the pre-clinical stage. YM155 (sepantronium bromide) is the first small molecule 
inhibitor believed to be targeting the expression of survivin, identified via high 
throughput screening (HTS) using a survivin-promoter-luciferase reporter assay 
aiming to identify small molecule inhibitors that may bind to the promoter 
sequence of the survivin gene [141]. YM155 potently inhibited survivin-promoter-
driven luciferase expression without effect on the expression of other 
antiapoptotic proteins. It also effectively inhibited growth of human prostate PC3 
ectopic xenograft tumors. In a follow-up study, YM155 induced cell death with an 
average IC50 of 15 nM in a panel of 119 human cancer cell lines [142]. 
Continuous 3- or 7- day YM155 infusion in xenograft models also showed 
significant tumor suppressing activity on different tumors including melanoma 
and cancers of breast, lung, and bladder without significant toxicity as indicated 
by little body weight loss.  
Due to the promise of YM155 in cell-based and preclinical studies, it has 
been investigated in clinical trials as a single agent and in combination with other 
anticancer therapies [143]. While YM155 is well tolerated with a MTD of 4.8 
mg/m2 and it has shown some efficacy against blood cancers, mixed results 
were generated when tested against various solid tumors with modest efficacy at 
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best for some tumors [144]. For example, no improvement in response rate was 
observed for non-small cell lung cancer patients in multiple phase II trials of 
YM155 as a single agent and in combination with carboplatin and paclitaxel [145, 
146] while a phase II trial of castration resistant prostate cancers (CRPC) 
showed modest activity with 25% of patients displaying prolonged stable disease 
[147]. While the modest successes in clinical studies suggest that targeting 
survivin may help identify a novel approach of cancer treatments, successful 
clinical development of YM155 is now questionable. Additionally, one major 
problem with YM155 is that it cannot be used for bolus dosing and has to be 
continuously infused 24 hours a day in 3- or 7-day dosing cycles. Currently, there 
are no ongoing clinical trials with YM155. Since the discovery of YM155, there 
have been large undertakings to determine its precise mechanism of action. 
While it has been shown to inhibit survivin transcription, it does not work via 
binding to survivin promoter sequence as anticipated but rather by inhibiting the 
survivin upstream transcription factor Sp1 [148]. Evidence also exists to suggest 
that YM155 may inhibit survivin expression by disrupting interleukin enhancer-
binding protein factor 3 and p54nrb complex, a critical complex for transcription of 
survivin [149]. There is also compelling evidence to suggest that YM155 may be 
a DNA damage-inducing agent [150] and its inhibition of survivin expression may 
be secondary to this event. Considering that Sp1, the target of YM155, is a 
ubiquitous transcription factor and that its inhibition of survivin expression may be 
a secondary event to DNA damages, designating YM155 as a survivin inhibitor is 
inappropriate and misleading.  
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EM-1421 (terameprocol) is another small molecule transcriptional 
repressor of the survivin gene under development as survivin inhibitor by Erimos 
Pharmaceuticals that acts to inhibit the ubiquitous transcription factor Sp1 [151]. 
In addition to inhibiting survivin expression, EM-1421 has been shown to also 
inhibit the expression of cdc2, another Sp1-controlled gene [152]. EM-1421 
induced G2 cell cycle arrest in a variety of solid tumor cell lines [153] and 
systemic treatment with EM-1421 suppressed the growth of human tumor 
xenografts including breast, prostate, colorectal, and liver cancers [154]. Using 
clonogenic survival assays, it was found that EM-1421 was able to induce radio 
sensitization in non-small cell lung cancer cells [155]. Similar as YM155, EM-
1421 has been tested in clinical trials. For advanced leukemia patients, EM-1421 
demonstrated a safe profile and showed partial responses in a few patients with 
CML or AML in a phase I study [156]. However, in a phase I study for high grade 
gliomas, EM-1421 did not display any response but stable disease was observed 
in 32% of patients [157]. Most recently, the safety profile of EM-1421 was tested 
as a vaginal ointment for treatment of Cervical Intraepithelial Neoplasia caused 
by human papilloma virus [158] in a Phase I/II trial using healthy adult women. 
The ointment with 1% and 2% EM-1421 showed a promising safety profile with 
no severe adverse effects in healthy subjects.  
SF002-96-1 is a natural drimane sesquiterpene lactone isolated from 
Aspergillus that was identified to potentially inhibit survivin promoter activity using 
survivin-promoter-driven reporter assay in Colo320 cells [159], similarly as 
described above for identification of YM155. SF002-96-1 decreased Colo320 cell 
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viability and induced apoptosis as evidenced by increased caspase 3 activity and 
cleaved chromosomal DNA by DAPI staining. Further studies using promoter- 
reporter assay, SF002-96-1 was shown to inhibit the activity of transcription 
factors STAT3 and NF-κB but not TCF/β-catenin, which all regulates survivin 
transcription, and also decreased survivin mRNA and protein levels. Thus, 
SF002-96-1 may inhibit survivin expression by inhibiting its upstream 
transcription factors such as STAT3 and NF-κB. As with other nonspecific 
strategies, unexpected dose-limiting toxicities may result from the disruption of 
other genes besides survivin, which may limit the utility of SF002-96-1 going 
forward.  
FL118 is a nonselective small molecule inhibitor of survivin expression 
that structurally resembles the topoisomerase I inhibitor, irinotecan. FL118 
appears to inhibit survivin expression by disrupting survivin promoter activity. 
However, FL118 also down regulates the expression of Mcl-1, XIAP, and cIAP2. 
Strikingly, FL118 displayed greater anti-tumor activity in squamous cell 
carcinoma and colon cancer cell line-derived xenografts, as well as a patient-
derived head and neck cancer xenograft as compared to leading first line 
chemotherapeutics [160]. A detailed molecular mechanism of FL118 action is 
currently lacking but warranted with the promising in-vivo data. However, based 
on the studies of YM155, it is tempting to speculate that FL118 may also inhibit 
upstream transcription factors that regulate survivin expression. It may also be 
possible that the effect of FL118 on survivin expression is a secondary effect of 
DNA damage potentially induced by FL118 inhibition of topoisomerase (see 
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discussion above on YM155). GDP366 is a small molecule compound that has 
been found to reduce the mRNA and protein levels of both survivin and 
oncoprotein Op18. Treatment with GDP366 inhibits cancer cell proliferation both 
in vitro and in vivo [161]. Little data are available to evaluate GDP366 and more 
mechanistic studies are warranted to elucidate the mechanism of action by which 
GDP366 produces its effects on survivin expression and its potential as a cancer 
therapeutics.  
While YM155 and EM-1421 have been tested in clinical trials as “survivin 
transcription inhibitors”, the most common issues with all these inhibitors are that 
they are not selectively targeting survivin expression. Most of these inhibitors act 
on one or more upstream transcription factors that regulate the expression of 
survivin as well as many other downstream genes. Effectively, these inhibitors 
are not survivin inhibitors but rather transcription factor inhibitors. The lack of 
specificity of these inhibitors in targeting survivin transcription as identified using 
survivin promoter activity assay and designating these compounds as survivin 
inhibitors are indeed troubling. 
Although both YM155 and EM-1421 have generally been tolerated in 
clinical trials despite the fact that they both inhibit a ubiquitous transcription factor 
Sp1, their limited clinical efficacies suggest that targeting the survivin upstream 
transcription factors such as Sp1 to limit survivin expression may unlikely 
represent an appropriate strategy to target survivin for therapeutic development. 
It is also unclear if the other downstream target genes of these transcription 
factors may work against the inhibition of survivin expression in suppressing 
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cancers in the clinical setting. These findings also indicate that targeting Sp1 may 
not lead to effective cancer therapeutics for development.  
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Table 3. Small molecule inhibitors suppressing survivin expression. 
Name Structure Remark Reference 
YM155  Inhibitor of Sp1. 
In-vitro IC50 of 
~15 nM. 
Phase I and II 
trials with 
modest 
efficacy. 
 
[141], 
[142] 
EM-
1421 
 
Inhibitor of Sp1. 
In-vitro IC50 of 
5-40 µM. 
Phase I and II 
trials with 
partial 
response. 
 
[151], 
[152], 
[153], 
[154], 
[155] 
SF002-
96-1 
 Inhibitor of 
STAT3 and NF-
κB 
In-vitro IC50 of 
3.4 µM in 
inhibiting 
survivin 
promoter 
activity. 
 
[159] 
FL118  In-vitro IC50 of 
6-8 nM 
In-vivo 
xenograft 
models of colon 
and head and 
neck cancers 
 
[160] 
GDP366 
 
In-vitro IC50 of 
1 µM (colon 
cancer cell line) 
In-vivo 
xenograft 
model of colon 
cancer 
[161] 
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1.5.1.2 Inhibitors Targeting Survivin Interaction with Other Proteins  
Since survivin is known to work by binding to and interacting with many 
important cellular proteins, there have been various efforts in targeting survivin 
interaction with its binding partners (Table 4). The first in this category of 
inhibitors is called shepherdin, a peptide with a sequence (K79H SPGCAFL87) of 
survivin that inhibits Hsp90 interaction with survivin and destabilizes survivin 
[162]. Tagging the amino terminus of shepherdin to either helix III of the 
Antennapedia or HIV-/Tat sequence led to a cell permeable shepherdin that was 
able to accumulate in cells and inhibit survival of HeLa, PC3, and DU145 cells by 
inducing apoptosis without apparent effect on normal cells. The cell permeable 
shepherdin also effectively inhibited PC3 xenograft growth in vivo. Because 
shepherdin binds to Hsp90 and may destabilize many proteins including survivin, 
the cell death induced by shepherdin could be due to multiple factors regulated 
by Hsp90. It would be of interest to determine if a peptide with a sequence from 
Hsp90 that inhibits Hsp90 binding to survivin has similar effects as shepherdin.  
In another study searching for peptide mimetics interacting with survivin 
using yeast two-hybrid system, a peptide derived from heavy chain 1 of ferritin 
was identified to interact with survivin [163]. Interestingly, this peptide, when 
cloned into a disabled thioredoxin for purification of recombinant protein, was 
able to bind to survivin and suppress survivin expression and induce apoptosis in 
breast and glioma cancer cells. The reduced survivin expression appears to be 
proteasome dependent. However, these authors have also shown that the full-
length heavy chain 1 of ferritin does not interact with survivin. Thus, the peptide-
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induced survivin loss may not be via inhibition of survivin interaction with ferritin. 
It remains to be determined how this peptide derived from ferritin would induce 
loss of survivin and induce apoptosis of cancer cells. Using a shape-based 
structural screening for the second mitochondria-derived activator of caspase 
(SMAC) mimetic that would inhibit interaction between SMAC and IAP proteins, a 
novel hit compound, UC-112, was identified that significantly activate caspases in 
melanoma and prostate cancer cell lines [164]. Continuous treatment of A375 
melanoma xenograft tumors with UC- 112 for 3 weeks significantly inhibited 
tumor growth in a dose-dependent manner with little reduction in the body weight 
of the mice. Interestingly, UC-112 dose-dependently inhibited survivin expression 
as well as expression of other IAPs albeit to a less extent. Currently, it is 
unknown if UC-112 disrupts the interaction between SMAC and survivin or other 
IAPs. It is also unknown how UC-112 suppresses the expression of survivin and 
other IAPs. However, it appears that UC-112 may reduce their stability via 
proteasome-dependent manners. Computational docking analysis predicts that 
UC-112 may bind to the BIR domain of survivin although experimental evidence 
is needed to prove this binding. It also remains to be determined why disrupting 
the interaction between SMAC and IAPs by UC-112 would lead to degradation of 
IAPs. UC-112 likely has other unknown activities that would facilitate the 
degradation of survivin and other IAPs, such as changing the conformation of 
these proteins. Many questions remain to be answered in order to further 
develop UC-112 as a SMAC mimetics to inhibit survivin and/or other IAPs.  
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In a follow-up structure-activity relationship study, analogs of UC-112 were 
synthesized and analyzed [165]. One of the analogs, 4g, has an iso-propyl group 
substituted on the C-linker of UC-112 (Table 4) with a 4-fold increase in activity 
in growth inhibition of cancer cell lines and increased selectivity to survivin as 
compared to UC-112. 4g also proved effective in inhibiting the A375 melanoma 
xenograft in vivo similar as the parent compound UC-112. The successes of 
these studies certainly warrant further mechanistic investigation of SMAC 
mimetics as survivin inhibitor and for potential development. SMAC mimetics 
represent an approach that inhibit survivin interaction with other proteins by 
binding to survivin and, thus, eliminate other effects by binding to its partners as 
in the case of shepherdin. However, modification and optimization of SMAC 
mimetics are likely needed to increase its specificity to survivin over other IAPs, 
which may prove to be difficult since their binding site, the BIR domain, is the 
consensus signature domain of IAPs.  
Withanone is a herbal ligand from the plant Withania somnifera, which 
was predicted to also bind to the BIR domain of human survivin using 
computational docking analysis and to interfere the caspase inhibitory function of 
survivin [166] similar as UC-112. However, no experimental testing has been 
conducted on withanone to determine if it inhibits or binds to survivin although 
withanone has been shown previously to have mild activity in inhibiting 
proliferation of various cancer cell lines [167-169]. Clearly, more studies are 
needed to investigate if this natural product hold any promise in binding to 
survivin and inhibiting its interaction with SMAC.  
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In another study, the protein-protein interaction sites in survivin were 
analyzed in-silico and hotspot residues were identified and used to generate a 
potential pharmacophore that may interfere survivin interaction with its binding 
partner chromosome passenger complex (CPC) [170]. HIV protease inhibitors, 
particularly Indinavir, was found to match the pharmacophore. Although Indinavir 
was able to inhibit the survival of MDA-MB-231 breast cancer cells with an IC50 
greater than 500 μM, it is unknown if Indinavir binds to survivin and inhibits its 
interaction with its binding partners such as those involved in the formation of the 
CPC. Interestingly, Indinavir decreased the XIAP protein level and increased 
caspase 3 cleavage. It remains to be determined if this effect was via binding to 
and inhibiting survivin. It is noteworthy that another HIV protease inhibitor, 
Nelfinavir, has previously been shown to potentiate Imatinib cytotoxicity in 
meningioma and inhibited survivin expression [171] while Indinavir did not affect 
survivin expression. Thus, it is unclear if these HIV protease inhibitors actually 
bind to and inhibiting survivin interaction with its ligand proteins. Clearly, more 
studies remain to be conducted on these HIV protease inhibitors to determine if 
they bind to or act on survivin and can be repurposed as potential new anti-
cancer therapeutics by binding to and inhibit survivin. However, because of its 
high IC50 at 500 μM, Indinavir will unlikely be repurposed as a survivin-targeting 
anticancer drug.  
Due to lack of known enzymatic activities and, thus, lack of high 
throughput assays for survivin, Abbot Laboratories conducted an NMR- and 
affinity-based screening of their libraries for compounds binding to survivin and 
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identified Abbot 8 that binds to a pocket in survivin, with a Kd of 75 μM, that may 
affect protein-protein interaction [172]. Via structure-activity analysis, modification 
of Abbot 8 increased its affinity in binding to survivin. However, Abbot 8 and its 
analogs were not tested for their activity in suppressing cancer cells or in 
inhibiting survivin interaction with its binding partners in this initial report.  
Using Abbot 8 as a lead compound targeting a site that may affect protein-
protein interaction, three compounds (LLP3, LLP6, and LLP9) were synthesized 
and tested as survivin modulators [173]. While LLP6 has no effect on cancer 
cells, LLP3 and LLP9 were able to delay mitosis and inhibit proliferation of 
HUVEC and PC3 cells. When tested against two isogenic glioma cell lines, LLP3 
has an IC50 of 13.6-38.1 μM. LLP3 was shown to be able to disrupt the 
interaction between survivin and its binding partner Ran [174], which may be 
responsible for the anticancer activity of LLP3. Thus, Abbot 8 and the LLP 
derivatives may work by inhibiting survivin interaction with its binding partners. 
Additional studies are clearly needed to investigate the fate of survivin following 
the binding of LLP compounds and survivin release from its binding partners in 
the CPC. Similar to LLP3, S12 was identified as a survivin-targeting molecule 
capable of binding to a cavity in survivin that may induce conformational changes 
in the protein structure that disrupt normal functions of survivin [175]. S12 
treatment alters microtubule dynamics in cancer cells, resulting in disruption of 
spindle formation, misalignment of chromosomes during metaphase, and G2/M 
cell cycle arrest. S12 also inhibits cancer cell proliferation in vitro and suppresses 
growth of pancreatic xenograft tumors in a dose dependent manner without 
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effecting the overall expression of survivin. In an additional study, S12 also 
inhibited the proliferation and growth of sonic hedgehog driven medulloblastoma 
cancer cells by inducing cell cycle arrest and apoptosis [176]. The detailed 
mechanism of action of S12 and whether it affects survivin interaction with its 
binding partners is awaiting to be investigated.  
In summary, the strategy targeting survivin interaction with its binding 
partners helps circumvent the issues encountered in targeting upstream 
regulators of survivin expression. This strategy may result in true survivin 
inhibitors that bind directly to survivin protein. However, limitations also exist with 
this approach. First, inhibitors such as shepherdin do not bind to and inhibit 
survivin. Instead, it binds to and inhibits survivin’s binding partner Hsp90, which 
also regulates the stability of other proteins in addition to survivin. Thus, inhibitors 
such as shepherdin are not specific to survivin and may represent Hsp90 
inhibitors. Secondly, inhibitors such as UC-112 bind to the BIR domain, which is 
a consensus signature domain of IAPs. Thus, it may prove to be challenging to 
generate a true survivin selective inhibitor that does not affect other IAPs. Thirdly, 
it is currently unknown what other protein partners of survivin would be affected 
by the inhibitors such as LLP3 designed to inhibit survivin interaction with other 
protein partners. Finally, the data on the mechanism of action of this category of 
inhibitors, especially LLP compounds and S12, are limited for detailed evaluation. 
More studies are needed to determine the value of the strategy in targeting 
survivin interaction with its binding partners. 
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Table 4. Inhibitors targeting survivin interaction with its ligand proteins. 
Name Structure Remark Ref. 
Shepherdin 
 
In-vitro IC50 of 25-75 
µM. 
In-vivo xenograft 
model of prostate 
cancer line 
[162] 
UC-112  In-vitro IC50 of 2.1 
(0.7-3.4) µM. 
In-vivo xenograft 
models of melanoma 
 
[164] 
 
4g  In-vitro IC50 of 0.5 
µM. 
In-vivo model of 
melanoma cell line 
 
[164], 
[165] 
Withanone  In-silico prediction 
only. No 
experimental data 
 
 
 
[166], 
[167-
169] 
Indinavir  In-vitro IC50 of >500 
µM (MDA-MB-231) 
 
 
 
[170] 
Nelfinavir  Inhibits survivin 
expression. 
In-vivo xenograft of 
meningioma. 
[171] 
Abbot 8  In-vitro Kd of 75 µM 
 
 
[172] 
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LLP3  In-vitro IC50 of 13.6-
38.1 µM. 
In-vivo xenograft 
model of 
glioblastoma 
multiforme 
 
[173], 
[174] 
S12  In-vitro IC50 of 6-8 
nM (colorectal 
cancer cells) 
In-vivo xenograft 
models of pancreatic 
and 
medulloblastoma 
[175], 
[176] 
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1.5.1.3 Survivin Vaccine and Immunotherapy  
The fact that survivin is over-expressed in many cancers but not 
expressed in most adult normal tissues has led many to believe that it may have 
potential to serve as a cancer vaccine for immunotherapy. Although this concept 
is relatively new, there have been therapeutics fast tracked to clinical trials 
(Table 6). In one study, it was found that an 8-amino acid peptide survivin-2B80-
88 (A80YACNTSTL88), derived from survivin 2B, a splicing variant of survivin, 
binds to HLA-A24 and is recognized by CD8+ cytotoxic T lymphocytes [177]. 
Cytotoxic T lymphocytes induced by survivin-2B80–88 ex vivo are capable of 
recognizing and acting on cancer cells expressing HLA- A24 and presenting 
endogenously processed survivin-2B peptide in tumor cells. Also, HLA-A24- 
restricted cytotoxic T lymphocytes from peripheral blood mononuclear cells of 
HLA-A24+ breast, colorectal, and gastric cancer patients can be induced by the 
survivin-2B80–88 peptide and they effectively cause cytotoxicity against HLA-
A24+ but not HLA-A24- lung adenoma A549 cell line [178]. These data formed 
the basis for a phase I clinical trial using the survivin-2B80–88 peptide in patient 
with advanced or recurrent breast and colorectal cancers [179, 180]. Although 
survivin-2B80-88 was well tolerated, it unfortunately did not elicit significant 
clinical response alone or in combination with incomplete Fruend’s adjuvant in 
these patients.  
In a similar study, another survivin peptide mimetic SVN53-67/M57-KLH or 
SurVaxM that can be presented by MHC class I to induce CD8+ cytotoxic T 
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lymphocytes [181]. Immunization of C57BL/6 mice with this peptide resulted in 
rejection of orthotopic GL261 glioma xenografts. SVN53-67/M57 also stimulated 
cytotoxic T lymphocyte responses against human tumor cells of several different 
MHC class I haplotypes ex vivo. Currently, two ongoing clinical trials for newly 
diagnosed glioblastomas and multiple myelomas are actively recruiting 
participants to test the efficacy of SVN53-67/M57. 
Cancer immunotherapies targeting survivin certainly offers an exciting 
approach for treating cancers. The ability to direct the immune system to 
recognize and kill cancer cells is revolutionizing cancer therapy. While survivin 
peptides and mimetics have yet to demonstrate significant clinical efficacy in 
immunotherapy, it is promising that they appear to be well tolerated and do not 
produce apparent toxicities. Also, it may not induce aberrant immune reactions 
as some other immunotherapeutics. Clearly, this approach is exciting as it may 
be a way to produce a robust immune response specifically against cancer cells 
that overexpress survivin.  
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Table 5. Immunotherapies targeting survivin. 
  
Names Sequence Remark Reference 
Sur-2B80-88 AYACNTSTL Lack of clinical 
response in phase 
I trial 
[177], [178], 
[179, 180] 
 
 
SurVaxM 
 
 
DLAQCFFMFKELEG
W 
 
 
In-vivo glioma 
xenograft model. 
Clinical trials 
ongoing 
 
 
[181] 
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1.5.1.4 Inhibitors Targeting Survivin Homo-Dimerization 
Because survivin has no known enzymatic activities but works as a homo-
dimer, targeting its homo-dimerization for identifying and developing survivin 
inhibitors has recently been attempted [61]. This approach not only helps 
circumvent some of the issues encountered in targeting upstream regulators of 
survivin expression and result in true survivin inhibitors that bind directly to 
survivin proteins, it may also help eliminate survivin protein, resulting in 
spontaneous apoptosis due to survivin elimination. Because the homo-
dimerization interface of survivin is unique, the inhibitor to this site is likely to be 
selective to survivin over other IAPs.  
As discussed above, the buried accessible area in the homo-dimeric 
interface of a monomeric survivin is 550 Å2 and occupies only 6% of the total 
accessible area of a monomer (9,044 Å2) compared with ~20% in most other 
dimeric or oligomeric proteins. Thus, targeting the homo- dimerization interface to 
disrupt survivin homo-dimerization would be feasible. Furthermore, disrupting 
survivin homo-dimerization will lead to exposure of the hydrophobic dimeric 
interface, which would target the protein to proteasome for degradation. In a 
recent in-silico screening study targeting the critical dimerization residues 
following detailed computational analysis of the dimerization interface, a hit 
molecule, LQZ-7, was identified [61] (Table 5). LQZ-7 not only was able to 
specifically disrupt survivin dimerization and inhibit cancer cell survival, it was 
also able to induce survivin degradation in a proteasome-dependent manner. 
However, it had no effect on survivin transcription or synthesis.  
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Further analysis of LQZ-7 analogs led to identification of superior 
compounds including LQZ-7F that can more effectively disrupt survivin 
dimerization, cause proteasome-dependent survivin degradation, and inhibit 
cancer cell survival. The IC50 of LQZ-7F against a panel of human cancer cell 
lines ranged from 0.4-4.4 μM and it induced spontaneous apoptosis in these 
cancer cells. Using pull-down assay with immobilized LQZ-7F and purified 
survivin, it was found that LQZ-7 can directly bind to survivin, possibly to the 
interface for homo-dimerization. LQZ-7F also showed promising in-vivo activity in 
mice. It effectively inhibited the growth of PC3 xenograft tumors and reduced 
survivin protein in the xenograft tumors as expected. LQZ-7F was also well 
tolerated without affecting the body weight of the mice [61]. Future studies of 
LQZ-7F and other LQZ-7 analogs as well as further optimization may prove 
fruitful in targeting survivin homo- dimerization for developing novel true survivin-
targeting cancer drugs.  
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Table 6. Inhibitors targeting homo-dimerization of survivin. 
Name Structure Remark Reference 
LQZ-7  In-vitro IC50 of ~20 
µM for prostate 
cancer cell lines 
[61] 
LQZ-7F 
 
 
In-vitro IC50 of 2.4 
(0.4-4.4) µM for 
multiple cancer cell 
lines 
 
In-vivo xenograft 
model of prostate 
cancer 
[61] 
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Docking LQZ-7 and LQZ-7F in survivin revealed how they interact with the 
dimerization residues (Figure 7A and 7B). LQZ-7 has three important 
interactions with survivin via (a) H-bond between an aniline NH group of LQZ-7 
and Glu94 of survivin; (b) interaction between the substituted aniline in LQZ-7 
and Phe93, Phe101, and Leu98 in the hydrophobic pocket of survivin via p-p 
stacking and hydrophobic interaction; and (c) H-bond between the carboxylic 
acid of LQZ- 7 and Trp10 of survivin. LQZ-7F has two key interactions with 
survivin via (a) H-bond between the primary amine group of LQZ-7F and Glu94 
of survivin and (b) the tetracyclic furazanopyrazine ring of LQZ-7F interacts with 
Phe101, Phe93, Leu98, and Trp10 via p-p stacking and hydrophobic interactions. 
These interactions may effectively inhibit survivin homo-dimerization. 
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Figure 7. Predicted binding modes of LQZ-7 and LQZ-7F in survivin. 
Both LQZ-7 (A) and LQZ-7F (B) interact with important residues for 
survivin homo-dimerization including residues Leu98 and Phe101. 
Proposed hydrogen bonding between compounds and survivin backbone 
are represented by dashed red lines. From Peery and Zhang (2017). 
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Based on the above pre-clinical studies, targeting survivin by disrupting its 
homo- dimerization may be a good strategy going forward. Although it has been 
shown that LQZ-7 and LQZ-7F bind to survivin, disrupt survivin homo-
dimerization, and induce survivin degradation, it is yet unknown if they truly bind 
to the homo-dimerization interface of survivin as intended. Since this study is the 
only one that has shown targeting the homo-dimerization domain of survivin, 
caution needs to be taken when considering targeting survivin by disrupting its 
homo-dimerization.  
More independent studies are needed to demonstrate the feasibility of this 
strategy in targeting survivin and possibly other homo-dimeric proteins for 
therapeutic discovery. It is also noteworthy that targeting homo-dimerization is 
more challenging than targeting survivin interaction with other proteins. It will be 
very perplexing to establish a high throughput assay to investigate and target 
homo-dimerization. In-silico screening may have to be used for such studies as 
demonstrated by the study discussed above.  
 
  
  58 
1.6 Summary 
 Survivin has consistently been demonstrated to be a critical factor in tumor 
progression and resistance to chemotherapy. The fact that survivin is 
overexpressed in almost every cancer but not expressed in most adult normal 
tissues has positioned it as a strong tumor marker with a robust correlation to 
poor patient prognosis. Despite the limited response of currently available 
therapeutics targeting survivin in clinical trials, targeting survivin for cancer 
intervention remains a highly attractive option. The lack of efficacy and dose-
limiting toxicities in clinical trials despite strong pre-clinical data for some 
inhibitors may be attributable to a deficiency in true survivin-specific inhibition.  
Strategies that target survivin directly by methods such as immunotherapy or 
direct homo-dimerization inhibitors may hold the key to overcome some of the 
inadequacies of previous attempts in targeting survivin moving forward. There 
still exists a great need to test the combination of direct survivin inhibitors with 
current standard chemotherapies to shed light on potential synergistic drug 
effects that may overcome the drug resistance paradigm in many cancers. One 
can certainly envision a future in which novel direct survivin inhibitors are 
positioned in the clinic as standalone agents or in combination with current 
standard of care chemotherapies.  
Given the pre-clinical data, direct survivin inhibition may be most suitable 
as a member of a combination therapy in which the inhibition of survivin 
enhances the apoptotic response of tumor cells to apoptotic stimuli induced by 
chemotherapies. In this study, it was sought to determine if survivin is a 
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contributor to docetaxel resistance and the mechanism by which a survivin 
inhibitor may function. The data presented here lead to a new hypothesis that 
survivin overexpression can contribute to docetaxel resistance in prostate 
cancer. The goal of this work was to investigate three specific aims: (1) to 
implicate survivin overexpression as a molecular player in docetaxel resistant 
prostate cancer, (2) to perform optimization of survivin dimerization inhibitor LQZ-
7 backbone and identify its mechanism of action, (3) to perform structure activity 
relationship analysis of LQZ-7F backbone. The long term goal of this work is to 
identify a novel survivin inhibitor capable of killing cancer cells and possibly 
synergizing with docetaxel for future translational therapies for treatment of 
prostate cancer. 
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CHAPTER 2. MATERIALS AND METHODS 
Methods 
Cell Culture 
 Prostate cancer cell lines PC-3, C4-2, Du145, 22RV-1, and LNCAP were 
cultured in complete growth media, RPMI-1640 (Corning, Manassas, VA) 
supplemented with 10% Fetal Bovine Serum (Life Technologies-Gibco, Grand 
Island, NY). Cells were maintained at 37o C 5% CO2 water-jacketed incubator. 
When confluent, cells were split by washing the flask one time with sterile 1X 
PBS followed by the addition of 0.05% trypsin (Lonza, Walkersville, MD) to digest 
the cells. After 5 minutes the trypsin was neutralized with new medium and cells 
were counted and seeded for desired experiment [182]. Low passage cells were 
maintained by splitting every 3 days and low passage cells were frozen using 
freezing media (50% RPMI-1640, 40% FBS, 10% DMSO) and stored in liquid 
nitrogen. All media and cell lines used are summarized in Table 7.  
 
Stepwise Cell Selection Docetaxel Resistant Cells 
 The stepwise cell selection for the generation of docetaxel resistance cell 
lines began at a concentration 0.1 nM docetaxel for both Du145 and C4-2 which 
is well under the IC50 of these cell lines and was performed as previously 
described [183]. Briefly, for the selection process the desired concentration was 
added to the flask of cells and sensitive cells died off while resistant cells 
continued to proliferate. After the addition of docetaxel to the cells, surviving cells 
were allowed to recover to confluency before being split. Each concentration 
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stage was performed three times before increasing the docetaxel concentration. 
The selection process took roughly two weeks at each concentration. When cells 
were deemed ready, the concentration of docetaxel was approximately doubled 
and the same process was repeated. This process was stopped when the Du145 
cells reached 100 nM and C4-2 cells reached 70 nM. At this point the cells are 
maintained in the flask with these concentrations added freshly every 48 hours. 
The resistance to docetaxel was confirmed by methylene blue assay. 
 
Compounds 
 All compounds were kindly synthesized by Dr. Mingji Dai’s Lab at Purdue 
University in West Lafayette, Indiana. Compounds for in-vitro cell-based studies 
were all dissolved in 100% DMSO to make a stock solution of 10 mM that was 
aliquoted into small aliquots for use. Compounds were stored in solution in -20o 
C freezer for no more than a few months and freeze thaw cycles were avoided as 
much as possible. Compound powder was also stored with bottle sealed in 
parafilm at -20o C for long term storage. 
 
Western Blot Analysis 
 Cells were harvested for western blot analysis by washing with 1X cold 
PBS two times followed by scraping with a rubber policeman as previously 
described [184]. Cell pellets were collected by centrifugation at 500g for 5 
minutes. Pellets were either stored at -80 or lysed immediately for analysis. Lysis 
was performed by addition of tnn buffer (50mM Tris-HCl (pH 7.4), 150 mM NaCl, 
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20 mM EDTA (pH 8.0), 50 mM NaF, 0.5% NP-40, 1mM Na3VO4) with the 
addition of 20 µl 10% SDS, 10 µl 0.2M PMSF, and 140 µl 1M DTT to every 2 mL 
buffer right before use. Pellets were stored on ice for 30 minutes with vortexing of 
each tube every 10 minutes. Cell lysates were then sonicated on ice at 40% 
amplification. The cell lysates were collected by centrifugation at 13,000 RPM for 
10 minutes at 4o C. The supernatant was collected and aliquoted to a fresh 
microcentrifuge tube. Protein concentrations were calculated using Bradford 
Standard Assay [185]. 
 The desired amount of protein was loaded on to SDS-PAGE gel using 2X 
SDS loading buffer (100 mM Tris-Cl, pH 6.8, 4% (w/v) SDS, 0.2% (w/v) 
bromophenol blue, 20% (v/v) glycerol, 200 mM b-mercaptoethanol). Gels were 
run at a constant 20mA per gel for 1.5 to 2 hours. Gels were transferred to PVDF 
membranes overnight at constant 35 Volts at 4o C [186]. The next day the 
membranes were blocked in 5% milk in TBST (50 mM Tris, 150mM NaCl, pH 7.4, 
0.05% Tween) for 2 hours at room temperature. The membrane was then probed 
with the primary antibody based on manufacturer’s recommendations, most 
commonly 2 hours at room temperature. Blots were then washed three times for 
15 minutes each using 5% milk in TBST. Secondary antibody was probed for 1 
hour at room temperature based on manufacturer’s recommendations. 
Membranes were once again washed for three times for 15 minutes each. 
Protein bands were detected by the addition of ECL western blot detection 
reagent (GE Healthcare, Chicago, IL) and X-ray film exposure [187]. The 
antibodies used for these experiments are summarized in Table 8. 
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Methylene Blue Assay 
 The assay was performed similarly to as previously described[188]. 
Briefly, prostate cancer cells were seeded 2000-3500 per well (cell line 
dependent) and treated with drugs for 72 hours. All compound dilutions were 
performed in cell media containing a set amount of vehicle. After 72 hours, media 
was then removed, and cells were fixed with methanol (Fisher Scientific) for 30 
minutes and subsequently stained with 100 µL of 1% methylene blue (Sigma) 
(diluted in 10 mM borate buffer) for 1 hour.  The cells were then washed 3 times 
with 10 mM borate buffer and then allowed to air dry for 30 minutes. 100 µL of 
100% ethanol:0.1 M HCl (1:1) was added to each well to dissolve the methylene 
blue stain and absorbance was measured via spectrometry at 650 nM using a 96 
well-plate reader (Walther Hall Fifth Floor Common Area). After normalization to 
DMSO controls, the percent viabilities were graphed and IC50 concentrations 
were determined using Graph Pad Prism software. DMSO control did not show a 
difference from media alone cells. Common buffers and materials for these 
experiments are summarized in Table 9 and Table 10. 
 
Survivin Overexpression 
 The C4-2 cell line was selected for survivin overexpression as it has the 
hallmarks and characteristics that most resemble prostate cancer characteristics 
seen in patients (express PSA and AR protein as well as generally form 
osteoblastic lesions when metastasis occurs). Before performing the stable 
transfection, a kill curve with the chosen selection antibiotic geneticin (G418) was 
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performed to determine the appropriate amount of antibiotic required to kill the 
majority of cells but not every cell. For C4-2 cells it was determined that 800 
µg/mL was the appropriate concentration to perform the selection for the survivin 
plasmid. 
 For the stable transfection of pcDNA3.1 HA-tagged survivin and 
pcDNA3.1 empty vector plasmid a 10 cm dish format was utilized [189]. For each 
plasmid, 20 x 105 cells were transfected with 10 ug of either vector or survivin 
plasmid DNA. This was done by adding 10 ug of DNA to 700 µl of serum free 
media in a microcentrifuge tube. In another tube, 30 µl of metafectene pro 
(Biontex, Munchen, Germany) was added to 700 µl serum free media. These two 
tubes were combined carefully, gently mixed and stored for 20 minutes at room 
temperature. 9 mL of fresh media with serum was then added to each dish 
followed by addition of the DNA and transfection reagent mixture. The 
transfection was for 48 hours before each dish was split in a 1 to 10 ratio in to 
fresh new 10 cm dishes. The following day, G418 was added to the media and 
the selection for positive clones was performed. Every 72 hours fresh G418 and 
media were added to each dish until colonies able to be seen by the naked eye 
were visible. At such time, the colonies were picked using a p200 µl tip and 100 
µL of trypsin to help detach the colony. Each colony was carefully transferred to a 
48 well dish followed by addition of 900 µl of media containing G418. When each 
well reached confluency it was split by trypsinization and expanded to 2 new 
wells per clone in a 6 well plate. After confluency was reached at this stage one 
well was used for further growing up the clone in a t75 flask that would be used 
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to eventually confirm expression and other experiments. The other well was 
frozen down for a stock of each clone. 
 
SiRNA Transfection 
 For the transient survivin siRNA transfection a 6 well plate format was 
utilized with 2 x 105 cells per well. A total of 4 wells was seeded in the 6 well 
plate, 2 wells for scramble control siRNA and 2 wells for the survivin siRNA [190]. 
The cells were cultured for 24 hours before the transfection was performed. For 
the transfection protocol, 200 µl of Opti-MEM Medium (Life Technologies-Gibco, 
Grand Island, NY) was added to two different microcentrifuge tubes. To one tube, 
15 µl of survivin siRNA (10 µM stock) was added to one tube and 3 µl of 
scramble control siRNA (50 µM stock) to the other tube. In two more additional 
tubes, 200 µl Opti-MEM Medium was combined with 20 µl Lipo-RNAi Max 
transfection reagent (Invitrogen, Carlsbad, CA). The tubes containing siRNA and 
Lipo-RNAi max were combined, mixed gently and left at room temperature for 20 
minutes. Before addition of the siRNA to cells, the media in each well was 
changed to fresh complete RPMI-1640 10% FBS media (1 mL).  The 
siRNA/transfection reagent mixture was then added to each well at 200 µl/well. 
The transfection was performed for 48 hours before one well was split and used 
for methylene blue assay and the other well was harvested for western blot 
analysis.  
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Survivin Mammalian Two Hybrid  
The mammalian two hybrid assay was performed utilizing the ClonTech 
Matchmaker Mammalian Two Hybrid Assay kit [191]. Briefly, the coding region 
(~400bp) of survivin was cloned in to two different plasmids, the pM plasmid 
containing the GAL4-DNA Binding Domain and the pVP16 plasmid containing an 
activation domain. For this the survivin plasmid was used as a template to do 
PCR to amplify the survivin coding region with the following primers: 
 
SurF: 5’ 
AAGAATTCGGCGGCGGCGGCGGCGATGGGTGCCCCGACGTTGCCC 3’ 
SurR: 5’ AACTCGAGTCAATCCATGGCAGCCAGCTGCTC 3’ 
 
Once the PCR was complete, the survivin PCR fragment was inserted into 
the AT easy vector (Promega, Madison, WI). The PCR fragment was then 
removed from the plasmid with EcoR1, blunting, and Xho1 digestion. Then each 
plasmid, pM and pVP16 was digested with BamH1, blunted, and Sal1. Finally, a 
ligation was performed between the survivin PCR fragment and both the pM and 
pVP16 plasmids. Correct orientation and sequence was validated by sequencing 
using forward and reverse primers to survivin.   
These two plasmids (0.45 µg/well) along with the pGSEAP reporter 
plasmid (0.09 µg/well) and firefly luciferase plasmid (30 ng/well) were co-
transfected in to 1 x 105 Du145 cells per well in a 12 well plate [192]. Each 
condition was tested in triplicate. For experiments utilizing LQZ-7-3 the cells were 
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seeded then 24 hours later the transfection was performed. 48 hours later the 
media was changed, and cells were treated with DMSO or LQZ-7-3 for 24 hours. 
SEAP was detected utilizing the Takara ClonTech SEAP Great Escape 
chemiluminescence assay kit 2.0 and cells were lysed, and luciferase was 
measured to control for transfection efficiency. For statistical analysis RLU was 
normalized to luciferase value.   
 
Luciferase Assay 
 In conjunction with the mammalian two hybrid assay, 30 ng firefly 
luciferase was transfected in to each well for a transfection efficiency control 
[193]. For this assay the firefly substrate was first thawed in the dark. Media from 
each well was collected for the two-hybrid assay, and cells were washed with 1X 
sterile PBS. 300 µL of Passive Lysis Buffer from the Dual Luciferase Assay Kit 
(Promega, Madison, WI) was added to each well. The plate was put on a rocker 
at room temperature and shaken at high speed to lyse the cells for at least 20 
minutes. The plate was then viewed under the microscope to ensure the cells 
had lifted off the plate and lysed. The cells were transferred to fresh 
microcentrifuge tubes and collected by centrifugation for 5 minutes at 1560 RPM. 
Each tube was placed on a dry ice ethanol bath for 2 minutes. The tubes were 
then transferred to 37 degree water bath for 2 minutes. The freeze/thaw process 
was repeated for a total of 3 cycles. The samples were then spun at 12,000 RPM 
for 2 minutes. The supernatant was transferred to a fresh tube and used to 
perform the Luciferase Assay. For the assay 5 µL of sample and 25 µL of Firefly 
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Luciferase were added to a 12x75 mm Brand glass tube. The tube was shaken 
3-5 times and then loaded into the luciferase machine. The value was recorded 
in Relative Light Units and used to normalize the two hybrid data. 
 
IAP Family Member Degradation Assay 
 For this experiment C4-2 or PC-3 cells were plated in a 10 cm dish at 1 x 
106 cells per dish.  24 hours later the media was changed, and cells were treated 
with DMSO or LQZ-7-3 10 µM.  After 48 hours the cells were harvested, washed 
in PBS, and IAP family members level were evaluated using specific antibodies 
and Western Blotting. The antibodies were probed using the specification 
provided by the Cell Signaling IAP family antibody kit (Danvers, Ma). Stripping 
the blot and re-probing similarly sized proteins was avoided for fear of losing 
protein on the membrane.  
 
Survivin Cycloheximide Half-Life Assay  
 The effect of LQZ-7-3 on survivin half-life was performed as previously 
described [194]. Briefly, PC-3 or C4-2 cells were plated in a 10cm dish at 8 x 105 
cells and cultured for 24 hours. The dishes were then pretreated with 10 μmol/L 
cycloheximide for 1 hour followed by incubation with or without LQZ-7-3 10 µM 
for different times (0, 30 minutes, 60 minutes, 1 hour, 2 hours, 4 hours, and 6 
hours).  The cells were then harvested for Western Blot analysis for survivin. 
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Apoptosis Assay 
 The apoptosis assay was performed as detailed in the Annexin V-FITC kit 
from BioVision (Milpitas, CA) [195]. Briefly, apoptosis was induced by treatment 
with LQZ-7-3 at 3 µM  or LQZ-7F-1 200 nM for 24-48 hours. Cells were 
trypsinized and collected by centrifugation at 1500 RPM. Per manufacturer 
directions, the cell pellet was washed one time with 2 mL of standard cell growth 
media. Then, cells were resuspended in 500 ul of 1X binding buffer and 5 µL of 
annexin V-FITC and 5 µL of propidium iodide (50 µg/ml) was added to the cells. 
The cells were incubated at room temperature for 5 minutes in the dark then 
subjected to quantification by flow cytometry via excitation at 488 nm and 530 
nM. The flow cytometry was performed in the IU Simon Cancer Center Flow 
Cytometry Core. 
 
Proteasome Inhibitors Study 
 For the proteasome inhibitor rescue experiment, PC3 and C4-2 cells were 
seeded in 10-cm dishes at 8 × 105 cells/dish and cultured for 48 hours followed 
by replacement with fresh media containing DMSO control, 7 μmol/L MG132, or 
70 nmol/L bortezomib and incubation for 2 hours. LQZ-7-3 or LQZ-7F-1 was then 
added to the culture to final concentrations of 10 µM  and 500 nM respectively 
and incubated for additional 24 hours. The cells were then harvested and used 
for Western Blot analysis of survivin to determine if proteasome inhibitors rescue 
survivin induced degradation by the compounds. 
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PC-3 Xenograft Model 
 For the in vivo efficacy study, 3 x 106 PC-3 cells in media were implanted 
into the hind flanks of 6 week old NSG male mice.  For this procedure each 
mouse was first weighed and given an identifying feature (typically ear punch). 
Then the left hind flank was shaved and sterilized with ethanol. Cells were then 
carefully injected in normal growth media using a sterile 1 mL insulin syringe. 
After the tumor volume reached approximately 100 m3 in volume, the mice were 
randomized in to two groups (5 mice/group).  The mice were either given 200 µL 
vehicle (90% corn oil/10% DMSO) or LQZ-7-3 100 mg/kg vial oral gavage every 
other day for a total of ten treatments.  Before each treatment mouse bodyweight 
and tumor volume by caliper was measured.  At the end of the study mice were 
sacrificed, and tumors were extracted for western blot analysis and H&E staining 
of survivin.   
 
Statistical Analysis 
 All statistical analysis was performed using the program GraphPad Prism 
5. Each experiment was performed independently and at least 3 replicates of 
each experiment was performed to ensure consistent findings. Data presented is 
the mean ± standard deviation unless otherwise noted. All p-values were 
calculated using the Prism program via student t tests or one way ANOVA 
followed by post-hoc test depending on the number of groups being compared. 
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Materials 
 
Table 7.  Media and Cell Lines   
Cell Line Media FBS Origin/Characteristics 
Du145 RPMI 10% Prostate, metastasis 
brain, AR (-), PSA (-) 
PC-3 RPMI 10% Prostate, metastasis 
bone, AR (-), PSA (-) 
C4-2 RPMI 10% 
Prostate, Derived from 
LNCAP, AR (+), PSA 
(+) 
22Rv1 RPMI 10% Prostate, AR (+), PSA (+) 
LNCAP RPMI 10% 
Prostate, metastasis 
lymph node, AR (+), 
PSA (+) 
Du145-100 Doc 
RPMI with 
100 nM 
Docetaxel 
10% 
Du145 cells serially 
treated with Docetaxel 
until reaching 100 nM 
C4-2-70 Doc 
RPMI with 
70 nM 
Docetaxel 
10% 
C4-2 cells serially 
treated with Docetaxel 
until reaching 70 nM 
C4-2 Vector 
RPMI with 
200 ug/mL 
G418 
10% 
C4-2 cells transfected 
with pcDNA3.1 empty 
vector 
C4-2 HA-Survivin 
RPMI with 
200 ug/mL 
G418 
10% 
C4-2 cells transfected 
with pcDNA3.1 C-
terminus HA tagged 
Survivin 
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Table 8. Antibodies    
Name Company  Catalog # Dilution 
Actin Sigma JLA-20 1:2000 
Anti-Mouse Secondary Sigma A2554 1:3000 
Anti-Rabbit Secondary Sigma A0545 1:3000 
Anti-Rat Secondary  Sigma A9037 1:2000 
Caspase 3 Cell Signaling 9662 1:1000 
CIAP 1 Cell Signaling 7065 1:1000 
CIAP 2 Cell Signaling 3130 1:1000 
Cleaved Caspase 3 Cell Signaling 9661 1:200 
HA-Tag Sigma H6908 1:1000 
Survivin Cell Signaling 2808 1:1000 
XIAP Cell Signaling 2045 1:1000 
  
 
Table 9. Common Buffers and Dyes 
Buffer Make up 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 
TBS 50 mM Tris, 150mM NaCl, pH 7.4 
PBST 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
0.05% Tween 
TBST 50 mM Tris, 150mM NaCl, pH 7.4, 0.05% Tween 
TNN 
50mM Tris-HCl (pH7.4), 150 mM NaCl, 20 mM EDTA (pH 8.0), 50 
mM NaF, 0.5% NP-40, 1mM Na3VO4, before each use add 20 µl 
10% SDS, 10 µl 0.2M PMSF, and 140 µl 1M DTT to every 2 ml 
buffer. 
2X SDS 
loading 
100 mM Tris-Cl, pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol 
blue, 20% (v/v) glycerol, 200 mM 𝝱-mercaptoethanol 
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Table 10. Common Materials    
Reagents Company Cat # Location 
1-Kb Quick load ladder 
New England 
Biolabs N0552G Ipswich, Ma 
5-mL polystyrene round-
bottom tube with cell-strainer 
Cap Fisher 352235 USA 
Acrylamide/bis- 37.5:1 RPI 7732-18-5 
Mount 
Prospect, IL 
Ammonium Persulfate (APS) Fisher 7727-54-0 USA 
Annexin V-FITC BioVision 
NC933823
5 Milpitas, CA 
Docetaxel Apex BIO A4394 Houston, TX 
Dual-Luciferase Reporter 
Assay Promega E1960 Madison, WI 
ECL Western Blot detection 
reagent GE Healthcare RPN2106 Chicago, IL 
G418 TEKnova G5005 Hollister, CA 
Gel Loading Dye (6X) 
New England 
Biolabs B7025S Ipswich, Ma 
Hoechst Fisher 62249 USA 
Instant Milk Walmart  USA 
Lipofectamine RNAi Max Invitrogen 13778030 Carlsbad, CA 
Metafectene Pro Biontex T040 Germany 
Methylene Blue Hydrate Sigma M4159 St. Louis, MO 
Opti-MEM Media Gibco 51985091 
Grand Island, 
NY 
Plasmid Prep Invitrogen K210014 Carlsbad, CA 
Pre-stained Protein Ladder Fisher 26616 USA 
Protein Assay Kit Thermo Fisher 23200 Waltham, MA 
PureLink mRNA extraction kit Invitrogen 12183018A Carlsbad, CA 
PVDF Fisher 162-0184 USA 
Reporter Lysis 5X buffer Promega E397A Madison, WI 
TEMED Fisher 110-18-9 USA 
Thiazolyl Blue Tetrazolium 
Bromide Sigma M5655 St. Louis, MO 
Triton X 100 Sigma T8787 St. Louis, MO 
Trypsin Lonza CC-5012 
Walkersville, 
MD 
Tween20 Fisher BP337 USA 
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CHAPTER 3. SURVIVIN AND DOCETAXEL RESISTANCE 
3.1 Background and Rationale 
Castration-resistant prostate cancer (CRPC) remains the second most 
common cause of cancer related mortality in men [196]. After androgen 
deprivation has failed and the cancer has become castration resistant 
chemotherapy is utilized not as a curative agent but to extend the life of these 
patient population. As discussed, docetaxel is the first cytotoxic agent to show 
modest improvements in overall survival rate in patients with CRPC [33]. 
Unfortunately over half of these patients do not respond to treatment and 
ultimately all develop resistance [197].  
The mechanism mediating docetaxel resistance remains unknown. It has 
been postulated that tubulin mutations, overexpression of drug efflux pumps, and 
overexpression of Inhibitors of Apoptosis proteins may all be implicated in 
resistance to docetaxel chemotherapy [198]. However, survivin, an inhibitor of 
apoptosis family member, has been identified as a mediator of chemo-resistance 
due to its dual roles in cancer cell survival through inhibition of apoptosis and 
facilitation of cell cycle progression [199].  
 There have been a few limited studies that have linked survivin 
expression to correlation with clinically biologically aggressive and docetaxel 
resistant prostate cancer [200]. Similarly, downregulation of survivin expression 
with a nonspecific inhibitor has been shown capable of reversing taxane 
resistance in prostate cancer cells [201]. However, because this inhibitor is 
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nonspecific it likely is affecting a multitude of different targets in the cell and 
therefore it remains unclear if this reversal in resistance is in fact due to survivin.  
 In this chapter it was hypothesized that survivin overexpression 
contributes to docetaxel resistance in prostate cancer. The work in this aim will 
hopefully provide the foundational experiments necessary to begin to investigate 
a mechanistic role for survivin in docetaxel resistance. The long-term goal of this 
translational study is to develop clinically relevant direct survivin small molecule 
inhibitors capable of sensitizing CRPCs to standard clinical therapies such as 
docetaxel. The results provide evidence that survivin expression is strongly 
correlated to docetaxel response in prostate cancer cells, docetaxel resistant 
cells display greater levels of survivin than docetaxel sensitive parental cells, and 
knockdown or overexpression of survivin increases or decreases sensitivity to 
docetaxel respectively.  
 
3.2 Results 
3.2.1 Survivin Expression and Docetaxel Correlation Analysis 
 First, to investigate if survivin contributes to docetaxel resistance in 
prostate cancer, the level of survivin expression in five different prostate cancer 
cells lines was evaluated. The prostate cancer cell lines included four castration 
resistant cell lines: Du145, PC-3, C4-2, and 22Rv1, as well as one androgen 
dependent cell line, LNCAP. Du145 and PC-3 are cell lines derived from brain 
and bone metastasis respectively. 22Rv1 cell line derived from a PCa xenograft 
that was serially propagated in mice after castration-induced regression and 
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relapse of the parental, androgen-dependent CWR22 xenograft. LNCAP was 
derived from a lymph node metastasis and C4-2 were isolated from a LNCaP cell 
subcutaneous xenograft tumor in a castrated mouse. The western blot analysis 
for survivin expression of these five cell lines showed that Du145 had the highest 
level of survivin expression and LNCAP had the lowest level of survivin (Figure 
8). Interestingly, all of the castration resistant cell lines displayed a much higher 
level of survivin than the androgen dependent cell line. In fact, the C4-2 cell line 
that was derived from LNCAP cells had a greater than two fold increase in 
survivin level. The survivin antibody used for this experiment is a monoclonal 
survivin antibody that binds to residues near cysteine 60 of survivin and detects 
total endogenous human survivin. It does not cross react with other anti-apoptotic 
proteins but is limited by the fact that it does not differentiate potential isoforms of 
survivin. 
 In order to determine if the survivin expression level in these five cell lines 
correlates with cytotoxic response to docetaxel, a series of methylene blue 
assays was performed with each cell line. Methylene blue is a basic dye that is 
positively charged at pH 8.5. It binds electrostatically to negatively charged 
groups within cells, predominately phosphate moieties of nucleic acids and some 
charged groups in proteins in order to quantify cell number. The methylene blue 
assays showed similar results as the western blot analysis with Du145 having the 
highest IC50 value at 1.3 nM and LNCAP the lowest IC50 at 0.5 nM (Figure 9A).  
 To determine if the level of survivin expression correlates with docetaxel 
cytotoxicity, a correlation analysis was performed. The relative survivin level and 
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docetaxel IC50 had a strong positive correlation as the higher the survivin level 
the higher the docetaxel IC50 (Figure 9B). This was confirmed by a high R2  or 
coefficient of determination of 0.902 which represent a goodness of fit test with 
closer to be 1 a perfect fit. These data indicate that survivin expression is 
correlated to the docetaxel IC50.  
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Figure 8. Survivin protein level is higher in castration resistant cell 
lines than androgen dependent cell lines. The four castration 
resistant cell lines have a higher level of survivin normalized to actin 
than androgen dependent cell lines. The error bars indicated standard 
deviation. n = 3 independent experiments. 
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y = 0.8995x + 
0.0342 
R² = 0.902 
Figure 9. Survivin protein level correlates with 
docetaxel IC50. (A) Average IC50 of methylene blue 
analysis of five prostate cancer cell lines. The IC50 was 
determined at 72 hour timepoint. Each concentration was 
tested in triplicate. Error bars represent standard deviation. 
(B) Correlation analysis of relative survivin level vs 
docetaxel IC50. Strong positive R2 = 0.902. n = 3 
independent experiments.  
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3.2.2 Survivin Expression in Docetaxel Resistant Cell Lines vs. Parental Cells 
 In order to assess survivin potentially being a component of docetaxel 
resistance in prostate cancer, an in vitro model of stepwise cell selection was 
used in which two different prostate cancer cell lines were serially exposed to 
increasing concentration of docetaxel (Figure 10). For this selection I utilized two 
castration resistant cell lines, one with the highest and lowest levels of survivin, 
Du145 and C4-2 respectively. C4-2 cells have a number of characteristics that 
make them particularly desirable cell line for prostate cancer research. First, they 
have the nice feature of being generated from androgen dependent cell line, 
LNCAP. Secondly, they express prostate specific antigen and androgen receptor 
unlike some other prostate cancer cell lines. C4-2 cells also tend to form 
osteoblastic lesions when undergoing metastasis to the bone in vivo which 
correlates nicely to the osteoblastic lesions seen clinically in patients. 
 The Du145 cell line underwent ten total increasing escalations of 
docetaxel concentration from 0.1 nM to 100 nM. The C4-2 cell line underwent a 
total of 9 escalations of docetaxel from 0.1 nM to 70 nM. Once the cell selection 
process had been completed, resistance to docetaxel was confirmed by 
methylene blue assay. The Du145 cells were selected until 200 nM 
concentration, however for these studies Du145-100nM was utilized as 100 nM 
as it is the highest concentration of docetaxel one could expect to reach in a 
tumor and was consistent with the stepwise cell selection by other groups in the 
literature [202]. Du145-Doc cells had a significantly increased docetaxel IC50 of 
127.8 nM as compared to parental Du145 cells IC50 of 1.3 nM indicating 
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resistance to docetaxel (Figure 11A). C4-2-Doc cells also had a significantly 
increased docetaxel IC50 of 84 nM as compared to parental C4-2 cells IC50 of 0.7 
nM (Figure 11B). Next, the level of survivin protein in stepwise selected resistant 
cells versus parental cells was determined by western blot. Du145-Doc cells 
showed a fivefold increase in relative survivin level compared to parental Du145 
cells (Figure 12A). More importantly, the increased survivin protein expression 
was concentration dependent. C4-2 Doc cells also showed a significant four-fold 
increase in relative survivin level compared to parental C4-2 cells (Figure 12B). 
These data provide evidence that increased docetaxel resistance and exposure 
increases survivin protein level in prostate cancer cells. 
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Figure 10. Stepwise cell selection of Du145 and C4-2 cells by 
increasing exposure to docetaxel. Du145-Doc cells reached a 
maintenance concentration of 100 nM docetaxel after 10 total steps. C4-2 
Doc cells are maintained at 70 nM docetaxel after 9 total steps. Larger 
arrows meant to indicate a higher concentration of docetaxel used. Cells 
were allowed to grow to confluency a total of three times at each 
concentration step. Each step took roughly two weeks to complete. 
  83 
  
   
 
 
  
 
 
 
 
 
 
 
 
 
 
A 
B 
*** 
*** 
Figure 11. Stepwise selected cells are resistant to docetaxel. (A and 
B) Du145-Doc cells and C4-2 Doc cells methylene blue concentration 
curve is shifted to the right indicating decreased sensitivity to docetaxel 
and an increased IC50. Each concentration was tested in triplicate and 
the IC50 was determined at 72 hours post addition of docetaxel. n = 3 
independent experiments. *** = p-value <0.001. Error bars indicate 
standard deviation. 
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Figure 12. Stepwise selected cells have increased survivin 
expression. (A) Du145-Doc cells have five-fold increased relative 
survivin level. n = 3 independent experiments. *** = p-value <0.001.  
Error bars indicate standard deviation. (B) C4-2 Doc cells have four 
fold increased relative survivin level. n = 3 independent experiments. 
** = p-value <0.01. Error bars indicate standard deviation. 
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3.2.3 Survivin Overexpression and Knockdown Effect on Docetaxel Cytotoxicity 
 In order to more directly determine how manipulation of survivin level may 
effect sensitivity to docetaxel treatment, C4-2 survivin overexpressing cells were 
established. Previously in our lab, a C-terminus HA-tagged survivin insert was 
cloned in to a pcDNA3.1 vector. This construct and control pcDNA3.1 empty 
vector were stably transfected in to C4-2 cells using 800 µg/mL G418 selection to 
establish the C4-2 survivin and C4-2 vector cell lines necessary for this set of 
experiments. For the following experiment utilizing these stable cells, three 
biological replicates were performed utilizing early passage cells that had been 
frozen down at -80. 
 To confirm the expected survivin overexpression had been stably 
established in these cells, western blotting was performed for survivin (Figure 
13A). An HA-tagged antibody was also utilized as a source of secondary 
confirmation of overexpression plasmid. Due to the small size of survivin, the HA-
tag does result in a molecular weight shift as expected in the western blot 
confirming overexpression. This is consistent with previous experiments 
performed with a HA- Tag survivin construct in mammalian cells [173]. To assess 
if overexpression of survivin in these C4-2 altered response to docetaxel 
treatment, methylene blue assays were performed. Interestingly, C4-2 survivin 
cells had an IC50 of 1.3 nM compared to 0.5 nM IC50 for C4-2 Vector cells (Figure 
13B). The overexpression of survivin in these cells represented a greater than 
two fold increase in docetaxel required to kill fifty percent of the cells.  
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Figure 13. Cells stably overexpressing survivin are more resistant to 
docetaxel. (A) Western blot analysis of C4-2 Vector compared to C4-2 
Survivin overexpression cells. Since survivin is such a small protein the 
small molecular weight shift caused by HA-Tag is expected. HA antibody 
was used to confirm stable transfection of C-terminus HA tagged survivin. n 
= 3 independent experiments. ** = p-value <0.01. Error bars equal standard 
deviation (B) Methylene blue comparison of C4-2 Vector and C4-2 survivin 
cells. C4-2 survivin cells have significantly higher IC50 value compared to 
vector cells. Each concentration was tested in triplicate. n = 3 independent 
experiments. ** = p-value <0.01. Error bars equal standard deviation. 
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 Since our docetaxel resistant cell lines expressed a significantly higher 
level of survivin than our parental cell lines, it was also of particular interest to 
determine if transient knockdown of survivin using siRNA could result in a 
decreased resistance to docetaxel and lower the IC50 of these cells to closer to 
that of the parental cells. For this experiment the two docetaxel resistant cells 
lines were transiently transfected with 100 nM survivin siRNA, then split and 
plated for our standard methylene blue assays or western blot analysis. A 
scrambled siRNA transfection was performed in each cell line as a control.  
The knockdown of survivin was first confirmed in Du145-Doc and C4-2-
Doc by comparison to scramble siRNA transfected cells using western blot 
analysis (Figure 14A). Scramble siRNA is a negative control in which the 
nucleotide targeting sequence is randomly rearranged so that it should not target 
any known genes. This control is meant to serve as a control that should have 
similar gene expression profile of un-transfected cells. As expected, in both 
Du145-Doc and C4-2-Doc cells, transfection with survivin siRNA significantly 
reduced survivin protein level. To determine the effect of knocking down survivin 
in our resistant cells, a methylene blue assay was performed in comparison to 
scramble transfected cells. In both Du145-Doc and C4-2-Doc cells transfected 
with survivin siRNA, the concentration curves shifted significantly to the left, 
indicating a decrease in resistance to docetaxel (Figure 14B). Although the IC50 
was not lowered to that of the original Du145 and C4-2 parental cells before 
docetaxel exposure, this may be attributed to the stepwise selection process 
selecting for other factors that may confer resistance in these cells. However, the 
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data indicate stable overexpression of survivin decreases prostate cancer cell 
sensitivity to docetaxel and knockdown of survivin in resistant cells lines 
dramatically lowers these cells resistance to docetaxel. The dramatic decreases 
in IC50 after knockdown in the resistant cells suggests once again that survivin is 
a major contributor to docetaxel resistance in PCa cells. 
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Figure 14. Survivin knockdown by siRNA in docetaxel resistant cells 
decreases resistance to docetaxel treatment. (A) Western blot analysis of 
scramble siRNA or survivin siRNA in resistant cell lines. n = 3 independent 
experiments. *** = p-value <0.001. Error bars equal standard deviation. (B) 
Methylene blue comparison of scramble siRNA or survivin siRNA in resistant 
cell lines. Survivin siRNA transfected cells have significantly lowered IC50 
than scramble transfected cells. Each concentration was tested in triplicate. 
n = 3. *** = p-value <0.001. Error bars equal standard deviation. 
*** 
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3.2.4 Survivin Expression and Cisplatin/Doxorubicin Cytotoxicity Correlation 
Analysis 
 As noted above, survivin expression had a robust positive correlation with 
docetaxel cytotoxicity in the five different prostate cancer cell lines. In order to 
determine if other chemotherapeutics with different mechanisms of action also 
displayed this correlation in prostate cancer cells, methylene blue assays were 
performed using cisplatin and doxorubicin. Cisplatin is common 
chemotherapeutic for many solid cancers, like bladder cancer, that works as an 
alkylating agent preventing proper DNA repair and synthesis. Doxorubicin is a 
common chemotherapy for treatment of breast cancer that acts as a DNA 
intercalator and a topoisomerase II inhibitor. Interestingly, unlike docetaxel, 
cisplatin or doxorubicin did not show any correlation with survivin expression in 
prostate cancer cells with R2 values well below 0.1 (Figure 15). From our data it 
appears that survivin expression is uniquely correlated with docetaxel cytotoxicity 
in our prostate cancer cell setting. 
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Figure 15. Survivin expression does not correlate with cytotoxicity to 
cisplatin or doxorubicin in prostate cancer cells. Correlation analysis 
of survivin expression in prostate cancer cells and (A) cisplatin or (B) 
Doxorubicin cytotoxicity. Each concentration was tested in triplicate. n = 3 
independent experiments. R2 is the coefficient of determination value 
representing a goodness of fit test. Error bars equal standard deviation. 
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3.3 Concluding Remarks 
 The data from this chapter serves to implicate survivin as an important 
molecular player in docetaxel resistance in prostate cancer. The findings above 
show a strong positive correlation between survivin expression and docetaxel 
cytotoxicity. The same was not true for other solid tumor chemotherapeutics 
cisplatin and doxorubicin. Stepwise docetaxel selected cells displayed 
significantly increased survivin expression. Cells stably overexpressing survivin 
had increased resistance to docetaxel.  Survivin knockdown by siRNA in 
docetaxel resistant cells partially restored their response to docetaxel treatment. 
The data presented in this chapter serves to provide a foundation and rationale 
for exploring the molecular mechanism by which survivin may be promoting 
docetaxel resistance. More importantly, these data indicate survivin may be an 
important drug target in docetaxel resistance and its inhibition may help restore 
cancer cells sensitivity to drug treatment. 
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CHAPTER 4. LQZ-7 FLEXIBLE SCAFFOLD OPTIMIZATION 
4.1 Background and Rationale 
 It has been previously assumed that survivin should belong to a class of 
‘undruggable’ proteins due to its lack of enzymatic activities. As detailed above, 
every attempt at targeting survivin previously involved targeting the protein 
indirectly [131]. However, more recently our lab using a combination of 
computational analysis of survivin’s dimerization interface and in silico screening, 
identified the first direct small molecule inhibitor of survivin protein itself which 
targets the residues of Leu98 and Phe101 in the dimerization interface of survivin 
[61]. The inhibitor identified, LQZ-7, is thought to disrupt survivin dimerization, 
destabilize survivin, and lead to its clearance by the cellular mechanism such as 
the proteasome. This study represented the identification of the first small-
molecule inhibitor to target the survivin protein directly and provided a blueprint 
for development of more in silico screening based approaches to therapeutically 
target homodimeric proteins.   
In this chapter, it was hypothesized that an optimized analogue of LQZ-7 
scaffold targeting survivin will demonstrate enhanced anti-cancer activity in 
cancer cell lines and in a xenograft model as compared to the parental LQZ-7 
compound. After chemical synthesis of five unique LQZ-7 analogs by our 
collaborators, the above hypothesis was tested using several cell-based assays 
and a PC3 in vivo xenograft model. The data presented in chapter identified an 
active analogue, LQZ-7-3, which demonstrated enhanced potency in multiple 
prostate cancer cell lines and suppressed xenograft tumor growth in an oral 
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formulation. LQZ-7-3 also lead to PC-3 and C4-2 apoptosis as measured by 
cleaved caspase 3 and annexin v flow cytometry staining increases as well as 
proteasome dependent survivin degradation. In this chapter I hypothesized that 
an optimized LQZ-7 inhibitor would have improved cellular accumulation and 
potency, leading to improved cancer cell killing. The specific aim of this chapter 
was to elucidate any identified analogue’s mechanism of action and asses its 
potential as an anti-cancer agent. 
 
4.1.1 Discovery of LQZ-7 
 Survivin as a non-enzymatic protein represented a particularly unique 
challenge in order to target the survivin protein directly. However, our lab used 
the knowledge that exposure of the hydrophobic core interface of a dimeric 
protein can cause changes in protein folding that result in weakening of the 
protein structure and degradation by cellular clearance mechanisms of the 
proteasome or autophagy [203-205]. Therefore, survivin as a homodimeric 
protein could possibly be targeted by screening for compounds capable of 
inhibiting survivin dimerization. Inhibition of survivin dimerization should then 
result in its clearance and prevention of its role in promoting cell proliferation and 
inhibiting apoptosis that cancer cells take advantage of in order to continue to 
grow. The discovery of LQZ-7 ended up being a two prong process: molecular 
dynamic simulations of the survivin dimeric interface to identify the key core 
critical residues for dimerization and in silico screening of small molecule 
compounds that may inhibit survivin dimerization. 
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 Dr. Zhang and Dr. Liu took advantage of a new method they developed for 
identifying dimerization core units involved in homodimerization by a molecular 
dynamics simulation analysis of water trafficking assay [206, 207]. This analysis 
determined that survivin has a particularly large proportion of hydrophobic 
residues in the dimerization interface making it ideal candidate for an inhibitor 
that can disrupt dimerization and expose the hydrophobic core residues. This 
computational approach also identified that survivin has a singular dimerization 
core unit which consists of Leu98 and Phe101 from one chain and Leu98 and 
Phe101 from the other chain. Finally, the survivin dimerization core during the 
simulation had a 0.5 water/200ps exchange, which indicated very few molecules 
moved in and out of the core during the simulation, and is comparable to other 
homodimeric proteins like 14-3-3s [61]. In total, the molecular dynamics 
simulation indicated that survivin has a firmly sealed dimerization core promoted 
by Leu98 and Phe101 that may be suitable for disruption by small molecules. In 
fact a previous study has indicated that mutation of Leu98 to alanine causes 
disruption of survivin dimerization [208].  
 The second step in the discovery of LQZ-7 involved a structure based in 
silico screening of a 200,000 small molecule compound library to identify 
compounds capable of targeting Leu98 and Phe101. The program utilized for this 
screening was DOCK, in which the three-dimensional structure of survivin was 
programmed into the simulation and each compound was docked with survivin. 
The compounds were scored by multiple stages of energy scoring. The top 100 
compounds were selected from the top scoring compounds that obeyed 
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Lipinski’s rule of five for drug likeness and were from different structural clusters. 
Of the top 100 compounds, those that were commercially available were tested 
for their cytotoxic abilities in PC-3 and Du145 cells. Only six compounds, 
including LQZ-7, showed greater than 50% inhibition and were used in non-
denaturing PAGE analysis for inhibition of survivin dimerization. LQZ-7 was able 
to dose dependently inhibit survivin dimerization and not interfere with another 
control homodimeric dimerization protein, 14-3-3s. In a cell free translation 
experiment, LQZ-7 also inhibited the dimerization of nascent survivin protein. 
LQZ-7 is the primary hit utilized for the structure optimization experiments in the 
remaining sections. 
 
4.2 Results 
4.2.1 Generation of LQZ-7 Structural Analogues 
 The predicted binding modality of LQZ-7 using DOCK, involves the small 
molecule making critical hydrogen bonding interactions with the backbone of 
survivin. The first hydrogen bond is between the amine group positioned next to 
the methylated benzene ring and Glu94. The second hydrogen bond is between 
the carboxylic acid group of LQZ-7 and Trp10 of survivin. The final significant 
interaction of the small molecule with survivin involves hydrophobic interactions 
between the furazanopyrazine ring and the key dimerization residues Leu98 and 
Phe101 (Figure 6) [61].  
Our collaborator Dr. Mingji Dai at Purdue University graciously generated 
five structural analogues of LQZ-7 while trying to maintain or enhance the 
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interactions of the small molecules with the survivin backbone. Each analogue 
had the replacement of the oxadiazole moiety with a benzene ring that better fit 
in to the binding pocket in the survivin backbone. Each analogue also maintained 
the critical amine group and Glu94 hydrogen bonding interaction. The primary 
differences between the analogues and LQZ-7 was the replacement of the large 
bulky side chain and furazanopyrazine ring with moieties designed to better fit 
between the space between Leu98 and Phe101 with the idea in mind that the 
addition of atoms like fluorine may maintain key interactions and possibly provide 
a strong polar covalent bond between the small molecule and survivin (Figure 
16).  
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Figure 16. Chemical structures of five analogues generated of LQZ-7. 
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4.2.2 Analogues Cytotoxicity in Prostate Cancer Cells  
After development and synthesis of the five LQZ-7 structural analogues, 
the first goal was to assess the cytotoxic nature of the analogues in relation to 
the parental LQZ-7 compound in prostate cancer cell lines, PC-3 and C4-2 by 
performing methylene blue experiments. Cells were tested over a concentration 
range of 0.1 µM to 40 µM. After seventy-two hour treatment, cells were fixed and 
percent cell viabilities were calculated. Interestingly in both PC-3 and C4-2 cells, 
only one structural analog, LQZ-7-3, showed enhanced potency as demonstrated 
by a lower IC50 value in the methylene blue assay (Figure 17A and 17B). LQZ-7-
3 had an average IC50 value of 3-4.8 µM as compared 8-10 µM in the tested cell 
lines. LQZ-7-3 compound has the substitution of fluorinated benzene at the LQZ-
7 amine position as well as the addition of a fluorine on the 1-benzene ring. The 
other four structural analogues had significantly higher IC50 values than that of 
the parental LQZ-7 compound. From this data LQZ-7-3 was selected as the new 
lead compound and was used in additional studies to characterize its mechanism 
of action and effect on a PC-3 xenograft tumor in vivo.  
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Figure 17. Structural analogue LQZ-7-3 has enhanced 
cytotoxicity compared to LQZ-7. One-Way ANOVA analysis of 
the average IC50 values of each compound tested in (A) PC-3 cells 
and (B) C4-2 cells. Each concentration was tested in triplicate. One 
Way ANOVA p-value = < 0.001. Post-Hoc Bonferroni Test ** = p < 
0.01, * = p < 0.05. n = 3 independent experiments. Error bars 
equal standard deviation. 
 
  102 
4.2.3 Correlation Analysis of Survivin Expression and LQZ-7-3 Cytotoxicity  
 To assess the activity and selectivity towards survivin, I next performed a 
correlation analysis of survivin expression in five prostate cancer cell lines and 
the average LQZ-7-3 IC50 in each cell line. As previously shown in Figure 8, the 
four castration resistant cell lines had a higher survivin level than that of the 
androgen dependent LNCAP cell line. Similar results were seen when the IC50 of 
LQZ-7-3 was determined by methylene blue in each of the lines (Figure 18A).  
As shown in the correlation analysis (Figure 18B), the IC50 values strongly 
positively associate with the survivin protein level in these cell lines with a 
coefficient of determination of 0.79, indicating that LQZ-7-3 likely also 
suppresses the survival of these cancer cells through its action on survivin.  
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Figure 18. Survivin protein level correlates with LQZ-7-3 IC50. (A) 
Average IC50 of methylene blue analysis of five prostate cancer cell 
lines using analogue LQZ-7-3. Each concentration was tested in 
triplicate (B) Correlation analysis of relative survivin level vs docetaxel 
IC50. Strong positive R2 = 0.79. n = 3 independent experiments.  
y = 2.7376x + 0.8417 
R² = 0.79 
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4.2.4 Mammalian Two Hybrid Assay with Analogues 
 As this class of survivin inhibitors are designed to be exerting their action 
through interaction and disruption of survivin dimerization, I assessed LQZ-7-3 
ability to diminish survivin dimerization in an in vitro mammalian two hybrid 
assay. This assay assesses the ability of two proteins to interact and bring 
together the GAL4-DNA Binding Domain of one plasmid and the activation 
domain of another plasmid to turn on the transcription of Secreted Embryonic 
Alkaline Phosphatase (SEAP) reporter gene.  SEAP catalyzes the hydrolysis of 
p-Nitrophenyl phosphate to produce a yellow end product that can be measured 
in the collected culture media and read spectrophotometrically at 405 nm.  
As shown in Figure 19A, LQZ-7-3 significantly decreased the SEAP gene 
production in the group 1 set of plasmids containing each plasmid with the 
survivin coding region insert as compared to the basal level of SEAP in cells 
shown by group 4.  LQZ-7-3 also had no effect on the pM-53/pVP16-T group 2 
positive control. To determine if LQZ-7-3 decreased survivin dimerization greater 
than parental compound LQZ-7, I performed a similar mammalian two-hybrid 
assay. Whereas, both LQZ-7 and LQZ-7-3 decreased group 1 survivin containing 
plasmids interaction, LQZ-7-3 decreased survivin dimerization significantly 
greater than LQZ-7 (Figure 19B). LQZ-7-3 also decreased group 1 survivin 
plasmid dimerization greater than the other LQZ-7 analogues (Figure 19C). 
These findings provide additional evidence that LQZ-7-3 is working through 
disruption of survivin dimerization. 
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Figure 19. LQZ-7-3 disrupts survivin dimerization to a greater 
extent than LQZ-7.  (A) Mammalian two hybrid survivin dimerization 
assay showing decreased RLU value in the cells transfected with the 
survivin plasmids (Group 1) and treated with LQZ-7-3. Group 2 is a 
positive control for SEAP that involves interaction of pM-53 and 
pVP16-T plasmids. Group 4 are empty vector transfections to 
determine the basal level of SEAP in the cell media. *** = P-value < 
0.001. n = 3 independent experiments. (B) Mammalian two hybrid 
survivin dimerization assay showing decreased RLU value in the cells 
transfected with the survivin plasmids (group 1) and treated with LQZ-
7-3 to a greater extent than those treated with LQZ-7. *** = P-value < 
0.001.  ** = p-value < 0.01. n = 3 independent experiments. (C) Effect 
of analogues 1-5 on Group 1 Survivin plasmids in M2H assay only. *** 
= P-value < 0.001.  ** = p-value < 0.01. n = 3 independent 
experiments. Error bars equal standard deviation. Each transfection 
was performed in triplicate. 
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4.2.5 Survivin and IAP Family Members Degradation Assay 
 To further establish LQZ-7-3 selectivity towards survivin, the effect of LQZ-
7-3 treatment on survivin and other IAP Family member proteins level in prostate 
cancer cells was assessed by western blot analysis.  As shown in Figure 20A 
and 20B, 48 hour treatment with LQZ-7-3 decreased survivin protein level as 
compared to DMSO control in both PC-3 and C4-2 cells.  LQZ-7-3 also 
decreased survivin protein level more than cells treated with LQZ-7 compound.  
Interestingly, despite being in the same protein family and sharing similar domain 
features, LQZ-7-3 treatment did not change the expression level of other 
Inhibitors of Apoptosis: XIAP, CIAP1, or CIAP2. These results give additional 
evidence that the small molecule inhibitors targeting survivin have specificity for 
the intended target protein versus other BIR domain containing proteins. 
 
4.2.6 Survivin Stable Overexpression Effect on LQZ-7-3 Cytotoxicity 
 To determine if overexpression of survivin would alter the sensitivity of 
cancer cells to LQZ-7-3, the stable transfected an HA-Tagged Survivin C4-2 cells 
from previous studies were utilized in this experiment. To evaluate the effect of 
this overexpression on the sensitivity of these cells to LQZ-7-3, once again a 
methylene blue assay was performed. As shown in Figure 21, C4-2 Survivin 
cells had a significantly higher IC50 at roughly 7 µM as compared to C4-2 
pcDNA3.1 vector cells that had an IC50 of 2 µM. The data indicate that 
overexpression of survivin decreases sensitivity to LQZ-7-3 as expected. 
  
  108 
 
   A 
Beta-actin 
Survivin  
XIAP 
CIAP1 
CIAP2 
LQ
Z -
7 
10
 µ
M
 
  D
M
SO
 
  LQ
Z -
7 -
3 
10
 µ
M
 
PC3 
26 
 
17 
72 
55 
 
43 
72 
 
55 
95 
 
72 
55 
43 
 
34 
  109 
 
 
  
B 
Beta-actin 
Survivin  
XIAP 
CIAP1 
CIAP2 
LQ
Z-
7 
10
 µ
M
 
  D
M
SO
 
  LQ
Z-
7 -
3 
10
 µ
M
 
 
C4-2 
Figure 20. LQZ-7-3 decreases survivin level without altering other 
IAP family members levels. Western blot analysis for survivin protein 
level and other IAP protein level after treatment with LQZ-7 and LQZ-
7-3 in (A) PC-3 cells and (B) C4-2 cells. Survivin is decreased at 48 
hours with treatment with both survivin inhibitors but levels of other IAP 
family members do not decrease. LQZ-7-3 decreases survivin level 
greater than LQZ-7 treatment. n = 3 independent experiments. 
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Figure 21. Survivin stable overexpression decreases cancer 
cells sensitivity to LQZ-7-3. Overexpression of survivin results 
in a higher IC50 value for the LQZ-7-3 compound in a C4-2-
survivin stable overexpression cells compared to vector 
transfected cells in a methylene blue assay. Each concentration 
was tested in triplicate. *** = p-value < 0.001. n = 3 independent 
experiments. 
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4.2.7 LQZ-7-3 Survivin Degradation Time Course 
 In the previous degradation assay, LQZ-7-3 treatment led to survivin loss 
at 48 hours compared to DMSO treated cells. In order to determine the time at 
which there is a clear difference in survivin protein level after LQZ-7-3 treatment 
compared to DMSO control treated cells a degradation timepoint assay was 
performed. Both PC-3 and C4-2 cells were treated for 0, 2, 4, 8, 24, 48 hours 
with DMSO control or 10 µM LQZ-7-3 followed by western blotting analysis for 
survivin. It is important to note that survivin protein level can be heavily 
influenced by cell-cell contact, thus careful consideration was given to the cell 
density plated to ensure that no timepoint (particularly 48 hrs.) used >85% 
confluent cells. In PC-3 cells, survivin protein level had decreased as early as 2 
hours whereas the decrease in survivin protein level was not seen until 8 hours in 
C4-2 cells (Figure 22A and 22B). The most significant differences in the time 
course came at 24 hours and 48 hours for both cell lines. In total, LQZ-7-3 results 
in rapid loss of survivin protein in prostate cancer cells.  
 
 4.2.8 LQZ-7-3 Effect on Survivin Half-Life 
 Survivin is a dynamic protein with a short half-life in the cell. To assess if 
LQZ-7-3 treatment could result in a change in the half-life of survivin compared to 
DMSO treated cells, a cycloheximide assay was utilized. To this end, PC-3 and 
C4-2 cells were pretreated with cycloheximide for one hour to inhibit synthesis of 
new proteins followed by chasing with LQZ-7-3 or DMSO for different times. 
Cycloheximide remained in the culture the duration of the experiment. Similarly to 
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the time course cells were used at roughly 65-75% confluency to avoid dramatic 
increases in survivin expression associated with cell-cell contact. Figures 23A 
and 23B show that the half-life of DMSO control treated PC-3 cells is 2.27 hours 
and 2.17 hours in C4-2, which is consistent with previously reported half-life of 
survivin [209]. However, after treatment with LQZ-7-3 the half-life of survivin was 
22 minutes in PC-3 cells and 50 minutes in C4-2 cells. The data in this section 
illustrates LQZ-7-3 treatment results in a significant decrease in the half-life of 
survivin in prostate cancer cells. 
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Figure 22. LQZ-7-3 treatment decreases survivin protein level 
rapidly in prostate cancer cells. Time course of LQZ-7-3 treatment 
effect on survivin protein level at 0, 2, 4, 8, 24, 48 hours in (A) PC-3 
cells and (B) C4-2 cells. * = p-value < 0.05. *** = p-value < 0.001. n = 3 
independent experiments. 
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Figure 23. LQZ-7-3 treatment decreases survivin protein half-life in 
prostate cancer cells. Survivin half-life determined by cycloheximide 
assay in DMSO control and LQZ-7-3 treated (A) PC-3 and (B) C4-2 cells. 
Cells were pretreated with cycloheximide for one hour then chased with 
DMSO or LQZ-7-3 for different times. The curved graph represents the 
average exponential decay curve of three independent experiments. ** = 
p-value < 0.01. n = 3 independent experiments. 
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4.2.9 LQZ-7-3 and Proteasome Inhibitor Rescue Experiment  
 To determine if LQZ-7-3 promotes survivin degradation via proteasome, 
PC-3 and C4-2 cells were pretreated with two different proteasome inhibitors 
MG132 and bortezomib for two hours before treatment with the compound. As 
expected LQZ-7-3 reduced survivin level significantly as compared to DMSO 
control (Figure 24A and 24B). Interestingly, pretreatment with the proteasome 
inhibitors rescued the survivin to a similar level as seen in the DMSO treatment 
group. Thus, LQZ-7-3 likely promotes survivin degradation via the proteasome. 
 
4.2.10 Effect of LQZ-7-3 Treatment on PC-3 Cell Cycle 
 To asses if LQZ-7-3 treatment has an effect on the cell cycle of prostate 
cancer cells, a propidium iodide flow cytometry study was performed. 
Specifically, PC-3 cells were treated with the roughly the IC50 of LQZ-7-3 (4µM) 
for 48 hours and subsequently stained with propidium iodide and analyzed by 
flow cytometry. It is important to note this experiment was only performed a 
single time, but treatment with LQZ-7-3 in the PC-3 cell line did not show a 
discernible effect on the cell cycle compared to DMSO treated cells (Figure 25). 
Despite the limited scale and scope of this experiment, it did guide us to move on 
from cell cycle changes and to other potential mechanism for LQZ-7-3 activity, 
such as apoptosis.  
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Figure 24. Pretreatment with proteasome inhibitors rescues LQZ-7-3 
induced survivin degradation. Survivin loss caused by 24 hour treatment 
with LQZ-7-3 was able to be restored by blocking proteasome activity via 
pretreatment with two different inhibitors 7 μmol/L MG132, or 70 nmol/L 
bortezomib and incubation for 2 hours in (A) PC-3 and (B) C4-2 cells. 
Survivin level was nearly completely rescued to DMSO control level. *** = 
p-value < 0.001. n = 3 independent experiments. Error bars equal standard 
deviation. 
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Figure 25. LQZ-7-3 treatment does not change PC-3 cell 
cycle status. Cell cycle differences between DMSO and LQZ-7-
3 4 µM treated PC-3 cells was assessed at 48 hours via 
propidium iodide staining and flow cytometry. Despite being a 
single experiment no cell cycle differences were evident between 
the two treatment conditions. n = 1 experiments.  
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4.2.11 LQZ-7-3 induces spontaneous apoptosis  
 Since it has been previously demonstrated that dominant negative forms 
of survivin may cause spontaneous apoptosis of cancer cells [126] I next tested if 
LQZ-7-3 also induces apoptosis through its inhibition of survivin. To determine if 
LQZ-7-3 induces apoptosis of cancer cells Flow Cytometry with Annexin V 
staining was performed. Treatment with 3 µM LQZ-7-3 generated 3.5 and 19.03 
relative fold increase in apoptosis in PC-3 and C4-2 cells respectively (Figure 
26A and 26B). In order to validate the apoptosis data from the annexin v 
staining, western blotting analysis was performed utilizing an apoptosis marker, 
cleaved caspase 3, which is activated and protein levels increase during the 
apoptosis cascade. As shown in Figures 27A and 27B, treatment with LQZ-7-3 
caused a dose dependent increase in cleaved caspase 3 levels in both PC-3 and 
C4-2 cells. Overall this section provides evidence that LQZ-7-3 promotes cancer 
cell death via apoptosis. 
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Figure 26. LQZ-7-3 treatment causes increased apoptosis in 
prostate cancer cells. Survivin loss caused by treatment with LQZ-7-
3 causes increased apoptosis in (A) PC-3 and (B) C4-2 cells as 
evidenced by increased Annexin V staining Flow Cytometry. *** = p-
value < 0.001. n = 3 independent experiments. Error bars equal 
standard deviation. 
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Figure 27. LQZ-7-3 treatment causes increased cleaved 
caspase 3 in cancer cells. Treatment with LQZ-7-3 leads to a 
dose dependent increase in cleaved caspase 3 levels as seen by 
western blot analysis in (A) PC-3 and (B) C4-2 cells. The increase 
in cleaved caspase 3 is confirmation of the flow cytometry data 
indicating increased apoptosis after LQZ-7-3 treatment. *** = p-
value < 0.001. n = 3 independent experiments. Error bars equal 
standard deviation. 
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4.2.12 Solubility, In Vivo Toxicity, and Efficacy of LQZ-7-3 
 In order to determine if LQZ-7-3 is orally available and efficacious as an 
anti-cancer agent, a PC-3 xenograft mouse model study was performed. 
However, before this work could proceed I sought to identify a suitable 
formulation for delivering LQZ-7-3 orally in vivo. 
4.2.12.1 Solubility 
 To determine the most suitable formulation for LQZ-7-3 to be given via 
oral gavage, multiple different solvents and combinations were tested. The 
different solvents tested to solubilize LQZ-7-3 included water, PBS, and multiple 
different oils. Eventually it was determined that a 90% corn oil and 10% DMSO 
best solubilized LQZ-7-3 up to 20 mg/mL without particulate formation. To make 
the stock solution for LQZ-7-3, the compound is first solubilized with 10% DMSO 
followed by the addition of the 90% corn oil.  
4.2.12.2 Acute Toxicity Study 
 Before beginning an in vivo efficacy study, safety profile of our LQZ-7-3 
corn oil/DMSO oral formulation was assessed by performing an acute toxicity 
study. The highest dose a mouse received was 200mg/kg for a total of four 
treatments every other day. This mouse showed no adverse effects or loss in 
body weight during the time of the study. This study was performed in such a 
manner as to simulate the dosing interval that would be used in a future efficacy 
study. The toxicity experiment was also meant to elucidate any dangers involved 
in this dosing strategy and the timeframe was designed to represent roughly the 
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half-way mark of a proposed efficacy study where decisions could be made to 
progress or end the study.  
4.2.12.3 LQZ-7-3 Efficacy Study 
 To determine if LQZ-7-3 is orally active in suppressing tumor growth, an in 
vivo PC-3 xenograft model was used in an efficacy study. For the efficacy study, 
3 x 106 PC-3 cells were first implanted subcutaneously in the hind flanks of six-
week old male NSG mice to establish xenograft tumors. When the tumor volume 
reached approximately ~100mm3 the mice were randomized, with five mice per 
group and treated with vehicle control (90% corn oil/10% DMSO) or 100 mg/kg 
LQZ-7-3 via oral gavage every other day for a total of ten treatments. As shown 
in Figure 28, at the end of treatment LQZ-7-3 treatment group had a significant 
decrease in tumor volume.  Although the tumor dry weight was not significant, 
LQZ-7-3 treatment group trended towards a decrease in tumor dry weight at the 
end of the study compared to vehicle group (Figure 29). Tumors in the LQZ-7-3 
treatment group tended to be smaller and less red in color as compared to those 
in the vehicle group (Figure 30). Importantly, throughout the study I did not see 
any adverse effects with mice remaining active, no visible signs of wasting, or 
changes in organ weight amongst the two groups. The bodyweight of mice 
remained constant with vehicle group after multiple rounds of dosing of LQZ-7-3 
suggesting that LQZ-7-3 doesn’t cause major toxicities (Figure 31A and 31B).  
These observations were similar to those seen in the short acute toxicity study 
that was performed before the efficacy study where I were able to perform 
multiple dosing up to 200mg/kg without decreases in body weight or adverse 
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effects. Western blot analysis of dissected xenograft tumors showed that the 
average survivin level in the LQZ-7-3 treatment group was dramatically 
decreased as compared to the vehicle group suggesting LQZ-7-3 may function to 
inhibit tumor xenograft growth by binding to survivin and promoting its 
degradation in vivo (Figure 32A). This finding was further validated by 
immunofluorescence of tissue sections from each group in which survivin, 
particularly in the nucleus, was dramatically reduced in the LQZ-7-3 treatment 
group as compared to the vehicle group (Figure 32B). 
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Figure 28. LQZ-7-3 oral formulation reduces tumor volume. 
Tumor volume over the course of the study in which each animal 
received a total of ten treatments one every other day. The final 
endpoint had LQZ-7-3 with a significantly lower tumor volume than 
vehicle treated group. The triangle arrows represent a day in which a 
treatment was given. * = p-value < 0.05. Error bars equal standard 
deviation. 
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Figure 29. LQZ-7-3 trends towards a decrease in dry tumor 
weight. Dry tumor weight after ten total treatments and 
conclusion of the study. The final endpoint had LQZ-7-3 
treatment group trending towards a significant decrease in 
tumor dry weight however one mouse tumor in the vehicle 
group did not graft as well as the others and remained quite 
small throughout the study.  
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Figure 30. LQZ-7-3 treatment results in smaller, less aggressive 
looking tumors. Tumors in the LQZ-7-3 treatment group appear to be 
smaller, less red and vascularized as compared to most of the tumors in 
the vehicle group.  
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Figure 31. LQZ-7-3 treatment did not result in observable 
toxicities over the course of the study. (A) Bodyweight did not 
noticeably decrease in either group during the efficacy study. (B) Dry 
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the two treatment groups at the time of sacrifice. Error bars indicate 
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Figure 32. LQZ-7-3 oral formulation treatment leads to decrease in 
target protein survivin. (A) Average survivin level after taking equal 
parts sample from each tumor in each group and performing western blot 
analysis. The LQZ-7-3 treatment group showed decrease target protein 
survivin levels as compared to average vehicle tumor. *** = p-value < 
0.001. n = 3 experimental repeats. Error bars indicate standard deviation. 
(B) Hematoxylin and eosin staining confirming tumor tissue and 
immunofluorescence staining demonstrating survivin decrease in tumors 
treated with LQZ-7-3, particularly in the nucleus. Staining was kindly 
performed by the Histology Core at The University of Toledo. 
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4.2.13 Combination Studies with Docetaxel 
 Although LQZ-7-3 was able to reduce tumor volume in a xenograft efficacy 
study after administration of an oral formulation, tumors were not entirely ablated 
in the treatment group. As it was the first time performing an efficacy study with 
one of the survivin inhibitors orally, there is likely dosing and formulation 
adjustments necessary to make the compound more successful in eliminating 
tumors in these animals. However, it is also possible that LQZ-7-3 may be more 
successful in a combinational therapy with more traditional treatments such as 
docetaxel. In order to assess the potential of administering LQZ-7-3 and 
docetaxel in a combination therapy in vivo, potential synergism between the two 
agents was first tested in cell based assays. 
 For the cell based assays the CI-isobol method was used to generate a 
combination index (CI) estimated from the known IC50 data of single drug 
treatments and then dose required to produce the same effect in combination 
treatments. The CI formula that was utilized is as follows: CI = CA,50/IC50,A + 
CB,50/IC50,B where IC50,A and IC50,B are the concentration of drug A and drug B 
that result in 50% inhibition in single drug treatments. CA,50 and CB,50 represent 
the concentration of drug a and drug b that provide the same effect in the 
combination treatment respectively. In this formula a CI value less than one 
indicates synergism, CI value equal to 1 is additive, and a CI over 1 is 
antagonism [210]. The results utilizing this method for LQZ-7-3 and docetaxel 
when given in a combination treatment at a 1:1 ratio of the IC50 to IC50 indicated 
strong synergism in both C4-2 and PC-3 cells with CI calculated well under 1 
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(Figure 33). This data provides support that a combination therapy between 
LQZ-7-3 and docetaxel may be beneficial and synergize in prostate cancer in 
vivo models. 
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Figure 33. LQZ-7-3 synergizes with docetaxel in vitro. 
Representative methylene response curves in combination treatments 
of LQZ-7-3 and docetaxel for (A) PC-3 cells and (B) C4-2 cells. (C) PC-
3 and (D) C4-2 cells Isobologram analysis demonstrating strong 
synergism between docetaxel and LQZ-7F-1 in. Each point represents 
the average of three independent experiments. (E) Summarized CI 
value for both cell lines.  
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4.2.14 LQZ-7 Analogues Functional Group Evaluation 
 The way in which the design and synthesis of the LQZ-7 structural 
analogues was performed has allowed for information to be garnered from the 
effect of different functional group additions to specific areas of the backbone of 
LQZ-7. Data from the cytotoxic and mammalian two hybrid assays was utilized to 
specifically assess the effect of additions of different moieties to the amine group 
in the LQZ-7 backbone. As shown in Figure 34, there was clear evidence that 
the addition of fluorinated benzene to the amine group established a significantly 
more potent compound in terms of cell cytotoxicity and ability to inhibit 
dimerization in the two hybrid assay than other analogues. The addition of methyl 
groups to the benzene ring also significantly decreased potency and ability to 
inhibit in the dimerization assay compared to fluorine atom alone. There was also 
no clear difference between bulky moieties like acetophenone, benzo-dioxolyl 
ethanone, o-xylene, or tert-butyl benzene rings in the assays utilized. Overall, the 
fluorinated benzene ring of LQZ-7-3 performed better than any other modalities 
in these experiments. 
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Figure 34. Functional group analysis of analogue changes at the 
amine group position of LQZ-7. LQZ-7-3 fluorinated benzene ring had 
enhanced cytotoxicity in cell lines as well as improved performance in 
dimerization assay compared to other functional group changes at the 
same position. 
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4.3 Concluding Remarks 
 The data in this section serve as a first generation optimization of the 
LQZ-7 survivin dimerization inhibitor backbone. In the outcomes above, a 
structural analogue of LQZ-7 was found that has enhanced cytotoxicity in 
prostate cancer cells and inhibits survivin dimerization in a mammalian two 
hybrid assay greater than the parental compound. The compound, LQZ-7-3, has 
a strong positive correlation between survivin expression and cytotoxicity in 
prostate cancer cell lines. LQZ-7-3 also appears to preferentially cause survivin 
degradation over other IAP family members. Survivin degradation after LQZ-7-3 
treatment occurs earlier than 24 hours in both PC-3 and C4-2 and LQZ-7-3 
significantly reduces the half-life of survivin. The loss of survivin  caused by LQZ-
7-3 is blocked by pretreatment with proteasome inhibitors suggesting LQZ-7-3 
induced survivin degradation is via the proteasome. LQZ-7-3 increases cellular 
apoptosis of prostate cancer cells compared to control as measured by annexin 
V staining and increases in cleaved caspase 3 protein levels. In a xenograft 
efficacy study, LQZ-7-3 reduced tumor volume after administration of ten oral 
treatments as compared to vehicle control. Importantly, LQZ-7-3 synergizes with 
docetaxel warranting the exploration of a combination therapy in future xenograft 
efficacy studies. Finally, the fluorinated benzene ring of LQZ-7-3 confers 
improved cellular responses in multiple assays as compared to other functional 
group substitutions at the same position of the LQZ-7 backbone. 
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CHAPTER 5. LQZ-7F-1 LOCKED SCAFFOLD OPTIMIZATION 
5.1 Background and Rationale 
 In the previous chapter, the discovery of the original hit compound, LQZ-7, 
and the next iterative generation analogue, LQZ-7-3 with enhanced cytotoxicity 
was characterized. The goal of this chapter was to examine a different compound 
with a more locked backbone, LQZ-7F, which was also identified in the same 
publication as LQZ-7. It was hypothesized that an optimized LQZ-7F inhibitor 
would have the greatest cytotoxicity in prostate cancer cells. The data in this 
section, identify a new lead compound, LQZ-7F-1, that has enhanced cellular 
cytotoxicity and promotes survivin degradation at substantially lower 
concentrations. The survivin loss resulting from LQZ-7F-1 treatment is also via a 
proteasome dependent mechanism. LQZ-7F-1 increases cellular apoptosis of 
prostate cancer cells as measured by flow cytometry and cleaved caspase 3 
protein level increases. The positive cellular data resulting from the use of this 
compound warrants future exploration in a in vivo xenograft efficacy study.  
 
5.1.1 Discovery of LQZ-7F 
 After the discovery of the original primary hit, LQZ-7, several analogues 
were generated and tested by similar means as before. One such compound, 
LQZ-7F, displayed more potent inhibition of cancer and had a strong positive 
correlation between survivin expression and cytotoxicity in these cancer cell 
lines. More importantly, in an in vivo xenograft efficacy model, LQZ-7F treatment 
via i.p. injection significantly inhibited the growth of prostate tumors growth [61]. 
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The interesting feature of LQZ-7F is that it was the only compound identified in 
the screenings that had a locked back bone conformation consisting of 2 five-
member rings and two-six member rings. The others compounds all consisted of 
a five member ring and dihydropyrazine ring connected other functional groups 
by amine groups creating this more flexible compound. The uniqueness of the 
backbone and preclinical success of this compound made this compound an 
ideal candidate for additional screening for an optimized structural derivative.  
 
5.2 Results 
5.2.1 LQZ-7F Analogue Generation 
 The first generation of LQZ-F structural analogues were synthesized 
maintaining the 4 ring backbone of LQZ-7F that is critical for the p-p stacking 
interactions with the dimerization core of survivin and changing the functional 
group attached to the cyclopentane ring. The idea behind additions of different 
functional groups at this position was to find an optimized functional group that 
strongly interacts with the survivin backbone. The functional group changes 
consisted of the addition of a simple carbonyl group to the cyclopentane to the 
addition of a complex n-amino-oxadiazolyl-butyramide group to the same 
position. The fifteen structural analogues of LQZ-7F are shown in Figure 35. 
  
  144 
 
 
  
Figure 35. Chemical structures of LQZ-7F analogues with substitutions 
at cyclopentane group. 
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5.2.2 LQZ-7F Analogues Single Concentration Analysis 
 In order to determine if any of the LQZ-7F structural analogues had a 
greater ability to promote cancer cell killing than LQZ-7F, a single concentration 
analysis was first performed in PC-3 and C4-2 cells. For this series of 
experiments, cells were treated with 2.5 µM of each different compound for 72 
hours. This concentration was specifically chosen as it represents the average 
IC50 value of LQZ-7F in prostate cancer cells. The results from the single 
concentration methylene blues are shown in Figure 36. As excepted, treatment 
of LQZ-7F at 2.5 µM inhibited both PC-3 and C4-2 roughly 50%. The only 
analogue that promoted cell killing to a greater extent than the parental 
compound was, LQZ-7F-1. This compound with the carbonyl substitution on the 
cyclopentane had less than 20% cells surviving in both cell lines after 72 hour 
treatment. The data in this section positioned LQZ-7F-1 for further in vitro testing 
to determine if may represent a more potent survivin inhibitor than LQZ-7F. 
 
5.2.3 LQZ-7F-1 Cytotoxicity  
 The results of the single concentration analysis indicated that LQZ-7F-1 is 
a more potent inhibitor than LQZ-7F. To clearly define the IC50 values of LQZ-7F 
in prostate cancer cells and additional methylene blue experiment was 
performed. PC-3 and C4-2 were tested with LQZ-7F-1 over a concentration 
range of 1 nM to 20 µM. As shown in Figure 37, LQZ-7F-1 had a significantly 
lower IC50 value than LQZ-7F-1 with IC50 values of 158 nM and 170 nM in PC-3 
and C4-2 respectively. In fact, LQZ-7F-1 represents the first survivin inhibitor 
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identified in the screening process to show a sub micromolar IC50 in cancer cells 
in vitro.  
  
  147 
 
 
 
 
 
  
PC-3
DM
SO
LQ
Z-7
F
7F
-1
7F
-2
7F
-3
7F
-4
7F
-5
7F
-6
7F
-7
7F
-8
7F
-9
7F
-10
7F
-11
7F
-12
7F
-13
7F
-14
7F
-15
0
50
100
Compounds
% 
ce
ll 
su
rv
iv
in
g
A 
*** 
*** 
  148 
 
 
 
  
  
C4-2
DM
SO
LQ
Z-7
F
7F
-1
7F
-2
7F
-3
7F
-4
7F
-5
7F
-6
7F
-7
7F
-8
7F
-9
7F
-10
7F
-11
7F
-12
7F
-13
7F
-14
7F
-15
0
50
100
Compounds
% 
ce
ll 
su
rv
iv
in
g
B 
*** 
*** 
Figure 36. Single concentration analysis of LQZ-7F and structural 
analogues. (A) PC-3 and (B) C4-2 cells were treated with 2.5 µM of 
each compound for 72 hours. The results indicate the percentage cells 
surviving after treatment. Only LQZ-7F-1 had a greater amount of cell 
killing as compared to parental LQZ-7F. Each data point was performed 
in triplicate. *** = p-value <0.001. n = 3 independent experiments. Error 
bars equal standard deviation. 
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Figure 37. LQZ-7F-1 is more potent inhibitor than LQZ-7F in 
prostate cancer cells. LQZ-7F-1 has a significantly lower IC50 
value in (A) PC-3 (158 nM) and (B) C4-2 (175 nM) cells than 
parental compound LQZ-7F. LQZ-7F-1 is the first sub micromolar 
inhibitor identified during screening. Each concentration was 
performed in triplicate.  *** = p-value < 0.001. n = 3 independent 
experiments. Error bars equal standard deviation. 
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5.2.4 Mammalian Two Hybrid LQZ-7F-1 
 After confirming the increase in potency by dose response curves, the 
next step was to establish that LQZ-7F-1 also exerts its function through 
disruption of survivin dimerization as expected. Similarly to the previous section, 
a mammalian two hybrid assay was performed to compare the dimerization 
inhibition by LQZ-7F and LQZ-7F-1 where group 1 represents the cloned survivin 
plasmids and group 4 are empty vectors controls for measuring basal RLU 
(SEAP) levels in the media. Treatment with LQZ-7F and LQZ-7F-1 both 
significantly reduced survivin dimerization in this assay (Figure 38). However, 
LQZ-7F-1 decreased SEAP reporter gene production in survivin containing 
plasmid group to a greater extent than LQZ-7F. Importantly, neither compound 
interfered with the empty vector controls relative light values. The data in this 
section indicates LQZ-7F-1 is not only a more potent inhibitor in terms of cell 
killing but also interfering with the intended target survivin’s dimerization.   
 
5.2.5 LQZ-7F-1 Cytotoxicity in Survivin Overexpression Cells 
 To determine if survivin overexpressing cells have a decreased sensitivity 
to LQZ-7F-1, C4-2 survivin stable overexpressing cells were once again used in 
a cell cytotoxicity assay. After 72 hour treatment, the C4-2 vector cells had an 
IC50 of roughly 200 nM, while C4-2 survivin cells had a significantly higher IC50 of 
947 nM (Figure 39). The data indicate that overexpression of survivin decreases 
sensitivity to LQZ-7F-1 as expected. 
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Figure 38. LQZ-7F-1 decreases survivin dimerization 
greater than LQZ-7F in a mammalian two hybrid assay. 
LQZ-7F-1 had a significantly lower normalized RLU value 
than LQZ-7F, indicating a decreases in survivin dimerization 
in the assay. Each compound was utilized at a concentration 
of 1 µM. Each transfection was performed in triplicate. *** = 
p-value <0.001. n = 3 independent experiments. Error bars 
equal standard deviation. 
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Figure 39. Survivin overexpression decreases sensitivity to LQZ-
7F-1. LQZ-7F-1 has a significantly higher IC50 value in survivin stable 
overexpression cells. As the intended target of LQZ-7F-1, one would 
expect increasing survivin levels would require more compound to 
overcome this increase. *** = p-value < 0.001. n = 3 independent 
experiments. Error bars equal standard deviation. 
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5.2.6 LQZ-7F-1 Survivin Degradation 
 Previous sections have illustrated that this group of survivin inhibitors 
upon treatment result in prompt survivin loss and degradation in the cell via 
interference with survivin dimerization interface. To confirm that LQZ-7F-1 also 
reduces target protein survivin levels in prostate cancer cells, a series of western 
blot analyses were performed. In PC-3 cells, both LQZ-7F and LQZ-7F-1 were 
treated at 1 µM for only 8 hours. LQZ-7F-1 robustly decreased survivin levels 
even as early as 8 hours in these cells (Figure 40). LQZ-7F-1 analogue also 
significantly decreases survivin levels greater than parental compound at this 
concentration and timepoint. In C4-2 cells, LQZ-7F was treated at 10 µM while 
LQZ-7F-1 concentration for treatment remained at 1 µM for 8 hours. As shown in 
Figure 41, LQZ-7F-1 even at a lower concentration significantly decreased 
survivin protein level greater than a higher concentration of LQZ-7F at an 8 hour 
timepoint. The data indicate LQZ-7F-1 is not only a more inhibitor but also 
causes survivin loss faster than the progenitor compound, LQZ-7F. 
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Figure 40. LQZ-7F-1 decreases survivin protein level greater 
than LQZ-7F. LQZ-7F-1 decreases survivin level significantly as 
early as 8 hours. This decreases is greater than that seen by 
parental compound LQZ-7F. This experiment was performed in 
PC-3 cells. *** = p-value < 0.001. n = 3 independent 
experiments. Error bar equals standard deviation. 
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Figure 41. LQZ-7F-1 decreases survivin protein level greater 
than previous generation inhibitor even at a significantly lower 
concentration. LQZ-7F-1 treated at 1 µM decreases survivin level 
significantly more than LQZ-7F at 10 µM. This experiment was 
performed in C4-2 cells. *** = p-value < 0.001. * = p-value < 0.05. n 
= 3 independent experiments. Error bar equals standard deviation. 
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5.2.7 LQZ-7F-1 and Proteasome Inhibitors Experiment 
 To determine if LQZ-7F-1 also promotes survivin degradation via 
proteasome, PC-3 and C4-2 cells were pretreated with two different proteasome 
inhibitors MG132 and bortezomib for two hours before treatment with the 
compound. As expected LQZ-7F-1 at 500 nM reduced survivin level significantly 
as compared to DMSO control (Figure 42A and 42B). Interestingly, pretreatment 
with the proteasome inhibitors rescued the survivin level to a similar level as 
seen in the DMSO treatment group. Thus, it appears LQZ-7F-1 treatment also 
promotes survivin degradation via the proteasome. 
 
5.2.8 Apoptosis Studies 
 To determine if LQZ-7F-1 also induces apoptosis of cancer cells Flow 
Cytometry with Annexin V staining was performed in coordination with the Flow 
Cytometry Core. Treatment with 200 nM LQZ-7F-1 generated 21.15 and 17.91 
relative fold apoptosis increase in PC-3 and C4-2 cells respectively (Figure 43A 
and 43B). In order to validate the apoptosis data from the annexin v staining, 
western blotting analysis was performed utilizing an apoptosis marker, cleaved 
caspase 3, which is activated and protein levels increase during the apoptosis 
cascade. As shown in Figure 44A and 44B, treatment with LQZ-7F-1 also 
caused an increase in cleaved caspase 3 levels in both PC-3 and C4-2 cells. 
Overall this section provides evidence that LQZ-7F-1 also promotes cancer cell 
death after survivin degradation by spontaneous apoptosis. 
 
  157 
17 
 
 
 
10 
55 
43 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
PC-3
DM
SO
LQ
Z-7
F-1
MG
13
2/L
QZ
-7F
-1
Bo
rt.
/LQ
Z-7
F-1
0
50
100
%
 R
el
at
iv
e 
S
ur
vi
vi
n 
Le
ve
l
 (
S
ur
vi
vi
n/
B
et
a 
A
ct
in
)
A 
Beta 
Actin 
Survivin 
D
M
SO
 
   LQ
Z -
7F
-1
 5
00
 n
M
 
  M
G
13
2 
+ 
LQ
Z-
7F
-1
 
   B
or
t +
 L
Q
Z -
7F
-1
 
*** 
  158 
26 
 
17 
55 
 
43 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C4-2
DM
SO
LQ
Z-7
F-1
MG
13
2/L
QZ
-7F
-1
Bo
rt./
LQ
Z-7
F-1
0
50
100
%
 R
ela
tiv
e 
Su
rv
ivi
n 
Le
ve
l
 (S
ur
viv
in
/B
et
a 
Ac
tin
)
B 
Beta 
Actin 
Survivin 
D
M
SO
 
  LQ
Z-
7F
- 1
 5
00
 n
M
 
   M
G
13
2 
+ 
LQ
Z-
7F
-1
 
   B
or
t +
 L
Q
Z-
7F
-1
 
Figure 42. Pretreatment with proteasome inhibitors rescues 
LQZ-7F-1 induced survivin degradation. Survivin loss caused by 
24 hour treatment with LQZ-7F-1 was able to be rescued by 
blocking proteasome activity via pretreatment with two different 
inhibitors 7 μmol/L MG132, or 70 nmol/L bortezomib for 2 hours in 
(A) PC-3 and (B) C4-2 cells. Survivin level was nearly completely 
rescued to DMSO control level. *** = p-value < 0.001. n = 3 
independent experiments. Error bar equals standard deviation. 
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Figure 43. LQZ-7F-1 treatment causes increased apoptosis in 
prostate cancer cells. Survivin loss caused by treatment with 
LQZ-7F-1 causes increased levels of apoptosis (A) PC-3 and (B) 
C4-2 cells as evidenced by increased Annexin V staining Flow 
Cytometry. *** = p-value < 0.001. n = 3 independent experiments. 
Error bar equals standard deviation. 
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Figure 44. LQZ-7F-1 treatment causes increased cleaved 
caspase 3 in prostate cancer cells. Treatment with LQZ-7F-1 
leads to an increase in cleaved caspase 3 levels as seen by 
western blot analysis in (A) PC-3 and (B) C4-2 cells. The 
increase in cleaved caspase 3 is confirmation of the Flow 
cytometry data indicating increased apoptosis after LQZ-7F-1 
treatment. ** = p-value < 0.01. n = 3 independent experiments. 
Error bar equals standard deviation. 
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5.2.9 Combination Studies with Docetaxel 
 As a future in vivo efficacy study utilizing LQZ-7F-1 alone and in 
combination with docetaxel is likely warranted due to the positive in vitro data, 
potential synergism between the two agents was first tested in cell based assays. 
For the cell based assays the CI-isobol method was once again used to generate 
a combination index (CI) estimated from the known IC50 data of single drug 
treatments and then dose required to produce the same effect in combination 
treatments. The results utilizing this method for LQZ-7F-1 and docetaxel when 
given in a combination treatment at a 1:1 ratio of the IC50 to IC50 indicated strong 
synergism in both C4-2 and PC-3 cells with CI calculated well under 1 (Figure 
45). Additionally using either agent in a 3:1 ratio also showed strong synergism in 
the tested cell lines. A 3:1 docetaxel to LQZ-7F-1 ratio displayed the lowest CI 
value in both PC-3 and C4-2 cells lines. The combination experiment results are 
detailed in the isobologram analysis (Figure 45D and E). This data provides 
support that a combination therapy between LQZ-7F-1 and docetaxel may be 
beneficial and synergize in prostate cancer in vivo models. 
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Ratio (IC50:IC50) C4-2 PC-3 
1 to 1 0.041 0.051 
3 Doc:1 LQZ-7F-1 0.026 0.025 
1 Doc:3 LQZ-7F-1 0.0273 0.034 
Figure 45. LQZ-7F-1 synergizes with docetaxel in vitro. 
Methylene response curves in combination treatments of 
docetaxel and LQZ-7F-1 in (A) 1:1 ratio, (B) 3 Doc:1 LQZ-7F-1 
ratio, (C) 1 Doc:3 LQZ-7F-1 ratio. Each data point was performed 
in triplicate. (D) PC-3 and (E) C4-2 cells Isobologram analysis 
demonstrating strong synergism between docetaxel and LQZ-7F-
1 in. Each point represents the average of three independent 
experiments. (F) Summarized CI value for both cell lines with 
different ratios tested. 
 
 
 
 
 
 
F 
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5.2.10 LQZ-7F Structure Activity Relationship Analysis 
 The design and synthesis of the LQZ-7F structural analogues was 
performed to allow for information to be garnered from the effect of different 
functional group additions to one specific position of the backbone of LQZ-7F. 
Data from the single concentration analysis in three different cell lines was 
utilized to specifically compare the effect of additions of different moieties to the 
cyclopentane group in the LQZ-7F backbone. As shown in Figure 46, there was 
clear evidence that the addition of a carbonyl functional group to the 
cyclopentane ring lead to a significantly more potent compound in terms of cell 
cytotoxicity and ability to inhibit dimerization in the two hybrid assay than other 
analogues. No other moieties increased the performance of any of the other 
analogues in comparison to LQZ-7F. In fact almost all of the analogues 
performed significantly worse than LQZ-7F in this series of experiments. Overall, 
the carbonyl group addition to form a cyclopentanone in the LQZ-7F-1 backbone 
established a compound with significantly lower IC50 value and increased effect 
on target protein survivin. 
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  Figure 46. Functional group analysis of analogue changes at the 
cyclopentane group position of LQZ-7F. LQZ-7F-1 has a carbonyl added 
to the cyclopentane had enhanced cytotoxicity in cell lines as well as 
improved performance in dimerization assay compared to other functional 
group changes at the same position. 
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5.2.11 Generation of LQZ-7F-1 Structural Analogues 
 The next iterative generation of survivin inhibitors were structural 
analogues of LQZ-7F-1 and were synthesized with changes that can be grouped 
into three broad categories. The first group of analogues have additional 
functional group changes at the cyclopentane group. The second group involves 
changes to the oxadiazine ring in the backbone. The final group involves the 
addition of different functional groups to the benzene ring in the LQZ-7F-1 
backbone. The idea behind this round of chemical synthesis of structural 
analogues was to garner further information on critical components of LQZ-7F-1 
compound that are critical for its function. The thirty structural analogues of LQZ-
7F-1 are shown in Figure 47. 
 
5.2.12 LQZ-7F-1 Analogues Single Concentration Analysis 
 In order to determine if any of the LQZ-7F-1 structural analogues had a 
greater ability to promote cancer cell killing than LQZ-7F-1, a single 
concentration analysis was first performed in PC-3 and C4-2 cells. For this series 
of experiments, cells were treated with 150 nM of each different compound for 72 
hours. This concentration was specifically chosen as it represents roughly the 
average IC50 value of LQZ-7F-1 in prostate cancer cells. The results from the 
single concentration methylene blue assays are shown in Figure 48. As 
excepted, treatment of LQZ-7F-1 at 150 µM inhibited both PC-3 and C4-2 
roughly 50-60%. While many analogues displayed activity, none generated in this 
round of synthesis had a greater cell killing effect than LQZ-7F-1. The data in this 
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section further positioned LQZ-7F-1 as the compound to use in future studies 
while also providing structure activity relationship insights in its backbone. 
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Figure 47. Chemical structures of LQZ-7F-1 analogues with 
substitutions at cyclopentane group, oxadiazine ring, or benzene ring 
of the parental compound’s backbone. 
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Figure 48. Single concentration analysis of LQZ-7F-1 and 
structural analogues. (A) PC-3 and (B) C4-2 cells were treated with 
150 nM of each compound for 72 hours. The results indicate the 
percentage cells surviving after treatment. No compound had greater 
amount of cell killing than parental LQZ-7F-1. Each concentration was 
tested in triplicate *** = p-value <0.001. n = 3 independent 
experiments. Error bar equals standard deviation. 
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5.2.13 LQZ-7F-1 Structure Activity Relationship Analysis 
 Although the synthesis of 30 structural analogues did not yield an 
improved compound in terms of performance in cell based assays, the strategic 
alterations at specific positions of LQZ-7F-1 helped further elucidate critical 
aspects of the compound. As detailed in Figure 49, there were three primary 
takeaways from the structure activity relationship analysis that was performed. 
First, the addition of the carbonyl group to the cyclopentane group (LQZ-7F-1) 
generated the most potent inhibitor in cytotoxicity and survivin inhibition assays. 
Secondly, the compounds that contained the oxadiazine ring in the ring 
backbone were more potent inhibitors of cell survival than those with a benzene 
ring at the same position. Finally, no functional group addition to the benzene 
ring of the backbone increased the potency of any of the inhibitors tested. 
  
  179 
 
 
 
 
 
 
  
Figure 49. Major takeaways from structural analysis of LQZ-7F and 
LQZ-7F-1 rounds of analogue generation. (1) The carbonyl group 
addition to the cyclopentane group (LQZ-7F-1 compound) formed the 
most potent compound. (2) Compounds with the oxadiazine ring were 
more potent than compounds with quinoxaline ring at the same position. 
(3) No functional group addition to the benzene ring of the backbone 
increases potency in cell based assays. 
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5.3 Concluding Remarks 
 The data in this section serve as a first generation optimization of the 
locked LQZ-7F survivin dimerization inhibitor backbone. In the experiments 
above, a structural analogue of LQZ-7F was found that has enhanced cytotoxicity 
in prostate cancer cells and inhibits survivin dimerization in a mammalian two 
hybrid assay greater than the parental compound. The compound, LQZ-7F-1, 
caused significant survivin degradation earlier than 8 hours in both PC-3 and C4-
2. The loss of survivin caused by LQZ-7F-1 treatment is blocked by pretreatment 
with proteasome inhibitors, suggesting LQZ-7F-1 induced survivin loss is via 
proteasome degradation. LQZ-7F-1 increases cellular apoptosis of prostate 
cancer cells compared to control as measured by annexin V staining and 
increases in cleaved caspase 3 protein levels. Importantly, LQZ-7F-1 synergizes 
with docetaxel, warranting the exploration of a combination therapy in future 
xenograft efficacy studies. Finally, the carbonyl group of LQZ-7F-1, which was 
added to the cyclopentane in LQZ-7F, confers improved cellular responses in 
multiple assays as compared to other functional group substitutions at the same 
position. 
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CHAPTER 6. DISCUSSION 
6.1 Summary of Findings and Discussion 
 Based on literature findings and data presented in Chapter 3, survivin 
appears to be a major contributor to docetaxel resistance. As summarized in 
Figure 50, based on data from Chapters 4-5, novel survivin inhibitors that block 
or disrupt survivin dimerization may lead to survivin protein degradation via the 
proteasome. The loss in survivin results in a decrease in survivin’s cellular 
functions and increased cell death by apoptosis. Direct survivin dimerization 
inhibitors may sensitize resistant cancer cells to docetaxel. Detailed summaries 
and discussion follow below. 
 
6.1.1 Survivin Contributes to Docetaxel Resistance in Prostate Cancer Cells 
 The data from Chapter 3 served to implicate survivin as an important 
molecular player in docetaxel resistance in prostate cancer. The survivin 
expression level in the five different prostate cancer cell lines tested had a strong 
positive correlation with docetaxel cytotoxicity. The same was not true for other 
solid tumor chemotherapeutics cisplatin and doxorubicin. Additionally, castration 
resistant and more aggressive cell lines had significantly higher survivin 
expression levels than androgen dependent LNCAP cells. In the in vitro model of 
stepwise docetaxel selection, docetaxel resistant cells showed significantly 
increased survivin expression to go along with their resistance to docetaxel. 
Comparatively, parental cells were sensitive to docetaxel and had lower survivin 
expression levels. In prostate cancer cells the stable overexpression of survivin 
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increased resistance to docetaxel and knockdown of survivin in docetaxel 
resistant cells partially restored their response to docetaxel treatment. The 
knockdown did not entirely return these cells to the sensitivity seen in the 
parental cell lines; however this can be contributed to the selection process 
invoking other factors of resistance besides survivin. It’s possible this process 
could lead to increases in the expression of drug efflux pumps like p-glycoprotein 
or other anti-apoptotic proteins such as Bcl-2 or Bcl-xl. A more suitable model for 
exploring the mechanism behind survivin specifically in the context of docetaxel 
resistance may be the use of patient-derived xenografts that over time are 
serially exposed to docetaxel and develop resistance. Although the detailed 
molecular mechanism of how survivin may mediate chemotherapeutic resistance 
continues to elude the field as a whole, the data presented in Chapter 3 serves 
to implicate survivin in the development of docetaxel resistance. More 
importantly, this data implicates survivin as a molecular player in docetaxel 
resistance. Further experiments are warranted to determine if inhibition of 
survivin may help restore cancer cells sensitivity to docetaxel treatment.  
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Figure 50. Summary of survivin inhibitors actions on prostate cancer 
cells. Survivin inhibitors targeting the dimerization interface of survivin, 
block or disrupt dimerization leading to increased degradation of survivin 
via the proteasome. The decrease in survivin leads to decreased survivin 
inhibition of caspase activation. This results in increased cleaved caspase 
levels and increased apoptosis leading to death of cancer cells. 
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6.1.2 LQZ-7-3 Inhibits Survivin Greater than its Predecessor and Reduces 
Prostate Cancer Xenograft Growth In Vivo 
 The data in Chapter 4 served as a first generation optimization of the 
LQZ-7 survivin dimerization inhibitor backbone that was discovered as the 
primary hit in our original in silico screening for compounds that could interact 
with the key core dimerization residues of survivin. A structural analogue of LQZ-
7 was found that has improved cytotoxicity in prostate cancer cells and inhibited 
survivin dimerization in a mammalian two hybrid assay greater than the parental 
compound. The compound, LQZ-7-3, also had a strong positive correlation 
between survivin expression and cytotoxicity in five different prostate cancer cell 
lines. In an IAP family degradation assay, LQZ-7-3 showed specificity toward 
promoting survivin degradation while not affecting other members of the IAP 
family’s protein level.  
Survivin degradation after LQZ-7-3 treatment occurred earlier than 24 
hours in both PC-3 and C4-2. Treatment with LQZ-7-3 also significantly reduced 
the half-life of survivin to well under one hour in both cell lines. Survivin 
degradation caused by treatment with LQZ-7-3 appears to be via the proteasome 
as two different proteasome inhibitors blocked the loss of survivin and restored 
the levels to that seen in the control treated cells. The loss of survivin by LQZ-7-3 
treatment appears to lead to spontaneous apoptosis of cancer cells as measured 
by annexin v staining and increased caspase 3 levels. In a mouse xenograft 
efficacy study, LQZ-7-3 reduced tumor volume after administration of ten oral 
treatments as compared to vehicle control. It’s important to note that 
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pharmacokinetic studies need to be performed on this compound to ensure 
optimal compound concentrations are being reached. Since tumors were not 
entirely eliminated in this study, LQ-7-3 may better positioned in this formulation 
to be a part of a combination treatment. In both PC-3 and C4-2 cells, the use of 
docetaxel and LQZ-7-3 in a one to one ratio at the IC50 of each drug lead to 
strong synergism. The data provided by the CI studies warrants a future efficacy 
study using docetaxel and LQZ-7-3 in combination to try to see a more robust 
elimination of prostate cancer tumors in the mice.  
 The meticulous design and synthesis of analogues with specific changes 
to the LQZ-7 backbone also allowed for a basic structure activity relationship 
analysis amongst this group of compounds. The addition of fluorinated benzene 
to the amine group established a significantly more potent compound in terms of 
cell cytotoxicity and ability to inhibit dimerization in the two hybrid assay than 
other analogues. Additionally, the substitution of methyl groups to the benzene 
ring also significantly decreased potency and ability to inhibit survivin 
dimerization as compared to fluorine atom alone. The addition of more bulky 
moieties in the other analogues decreased performance overall in the cell based 
assays. Overall, the fluorinated benzene ring of LQZ-7-3 performed better than 
any other functional group changes to LQZ-7 backbone. I postulate that this 
improvement in performance can be attributed to the improved solubility and cell 
permeability associated with fluorinated small molecules [211]. It is possible the 
addition of the fluorine moieties to LQZ-7-3 may also increase binding affinity to 
target protein survivin as seen previously in fluorine medicinal chemistry [212]. 
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Finally, it has been demonstrated fluorinated small molecules often have 
increased intrinsic potency and better pharmacokinetic properties than non-
fluorinated counterparts [213]. All of the possibilities mentioned above may 
contribute to LQZ-7-3 improved performance in assays and warrant further 
exploration. 
 
6.1.3 LQZ-7F-1 is a Potent Survivin Inhibitor in the Nanomolar Range 
 LQZ-7F was a special analogue generated from LQZ-7 that had distinct 
backbone unlike other compounds identified in previous screenings. This 
backbone consisted of four locked ring structures that result in a less flexible 
compound backbone. The data in Chapter 5 served as a first generation 
optimization of the locked LQZ-7F survivin dimerization inhibitor backbone. LQZ-
7F-1, a structural analogue of LQZ-7F, was found that has increased cytotoxicity 
in prostate cancer cells and inhibited survivin dimerization in a mammalian two 
hybrid assay greater than LQZ-7F. The compound, LQZ-7F-1, caused significant 
survivin degradation earlier than 8 hours in both PC-3 and C4-2. Similarly to 
LQZ-7-3, pretreatment with proteasome inhibitors rescued and restored survivin 
loss by LQZ-7F-1 to that of control levels. This further indicated that the class of 
survivin inhibitors presented here cause survivin degradation via the proteasome. 
The loss of survivin by LQZ-7F-1 also increased caspase 3 levels and lead to 
apoptosis of prostate cancer cells. As the data presented in the previous sections 
has indicated the possibility of survivin inhibitors being more successful in a 
combination therapy, it was promising to see strong synergism between 
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docetaxel and LQZ-7F-1 In the structure activity relationship analysis, the 
carbonyl group of LQZ-7F-1 which was added to the cyclopentane in LQZ-7F 
showed significant increases in potency obtaining a nanomolar IC50. The 
similarity between LQZ-7F and LQZ-7F-1 leads us to hypothesize that LQZ-7F-1 
may be an active metabolite product of LQZ-7F metabolism. This possibility is 
exciting and warrants further assessment in future studies. Overall, the strong 
performance of LQZ-7F-1 cell based assay activity warrants further investigation 
as a lead compound in efficacy studies. 
 
6.2 Points of Consideration 
 In this study, survivin was emphasized as an important cellular player in 
docetaxel resistance, and two primary lead compounds were identified for future 
efficacy studies as a single agent and combination therapy with docetaxel. There 
were not major obstacles encountered during the completion of this thesis 
besides minor technical adjustments required to optimize protocols. However, 
there may exist some potential limitations associated with the experiments 
presented here that warrant further discussion and evaluation going forward. 
 The use of 2D monolayer cell culture provides an easy, comparative 
method for the growth and analysis of cancer cells in culture. While 2D cultures 
have advanced the fields knowledge and allowed for greater understanding of 
cancer cell behaviors and mechanisms of resistance, the growth of cells on a flat 
surface has its limitations when trying to translate discoveries to in vivo systems. 
Currently, 2D cell cultures are often hyper-sensitive to anti-cancer agents and 
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also fail to the model for the dynamic interactions between cancer cells and their 
microenvironment. Consequently, these cell line models may not be the best for 
transitioning results to the physiology of in vivo models and actual patients.  
There is a still a lot of work to be done, however 3D cultures in the form of 
spheroids from cell lines and organoids from patient samples may better 
represent the dynamic interplay that occurs in a tumor. In these 3D cultures an 
extra-cellular matrix can surround the cells and allows for the interaction between 
the cancer cells and their microenvironment. The development of organoids from 
primary tumors or metastases from patients also allow for the study of cancer 
stem cells and microenvironment while also maintain tumor heterogeneity [214]. 
3D cultures generally have the problem that their complexity limits biological 
replicates and combination therapies are sometimes not practical, however more 
recently there has been the development of microwell-mesh 3D cultures that 
allow for the generation of roughly a hundred microtumors per well for screening 
anti-cancer compounds [215]. In future studies using the survivin inhibitory 
compounds, the microwell-mesh 3D organoids technique derived from patients 
may represent innovative tool for therapeutic screening that better reflects the 
responses in animals and patients.  
Finally, the other potential limitation associated with this study is the use of 
NSG mice for the in vivo xenograft efficacy study. These mice are 
immunodeficient meaning they lack mature T cells, B cells, and NK cells that 
make up a functioning immune system. Implantation of tumors in these mice are 
much easier as host rejection of human tumor cells becomes less likely however 
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this comes with a tradeoff. Since there is a deficiency in the immune system 
these mouse models are unable to replicate the interplay between the cancer 
cells, the tumor microenvironment, and mature host immune cells seen in 
patients. Therefore, there exists the strong possibility that a compound that 
shows promise and efficacy in these mice may not necessarily work in patients. 
More recently, researchers have sought to overcome these challenges 
particularly in prostate cancer. The development of patient-derived xenograft 
models (PDX) may provide a critical alternative that will allow for clinically 
relevant and translation data. The PDX models preserve the tumor-
microenvironment architecture and also the tumor heterogeneity [216]. 
Unfortunately, very few PDX models have been successfully established for 
prostate cancer. 
It is likely more appropriate for us going forward to implore an orthotopic 
syngeneic prostate cancer mouse model which possesses many advantages 
over subcutaneous injection of cancer cells or use of immunocompromised mice. 
First, orthotopic implantation involves injecting the cancer cells in to the organ of 
origin which allows for more clinically accurate vasculature, tumor 
microenvironment, and response to therapy [217]. There exists a number of 
established syngeneic mouse models for prostate cancer that allow for elegant 
experiments such as surgical castration to study castration resistant prostate 
cancer and even the use of fluorescent cancer cells to monitor there 
dissemination throughout the body over the course of the study. Syngeneic 
mouse models also allow for the use of immunocompetent mice and therefore 
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help maintain the dynamic interplay between cancer cells and host immune cells. 
Finally, syngeneic mouse models are often times less expensive than genetically 
engineered models. 
 
6.3 Future Directions 
The experiments above demonstrated exciting results like the 
development of more potent survivin inhibitors that represent the first to directly 
target the protein itself, as well as survivin appearing to be implicated as a large 
contributor to docetaxel resistant phenotype seen in prostate cancers. The 
results provide the foundation for exciting new studies to further our knowledge of 
docetaxel resistance and survivin’s cellular mechanism. 
The future studies will focus on the molecular mechanism of survivin 
mediating docetaxel resistance. For this set of experiments the two stepwise 
selected docetaxel resistant cell lines, C4-2-Doc and Du145-Doc, as well as their 
respective parental cell lines as controls would be the primary model utilized. 
Previously, it was observed that there is a significant overexpression of survivin 
in docetaxel resistant cell lines as compared to their respective parental cell line. 
Thus, the first study would be to determine the possible subcellular localization 
changes of survivin in resistant cells as compared to parental cells using 
immunofluorescence (IF) and cellular fractionation followed by western blot 
analysis.  
Next, to determine if survivin up-regulation in the docetaxel resistant cells 
can overcome docetaxel- induced G2/M arrest, knockdown of survivin in the 
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resistant cells and overexpression of survivin in parental cells would be 
performed. Then changes in these cells would be compared by FACs cell cycle 
analysis to see if altering survivin expression level affects docetaxel induced 
G2/M arrest. As survivin overexpression may mediate faster mitotic progression, 
one could also test if C4-2-Doc and Du145-Doc cells progress through the cell 
cycle faster than their parental cells using BrdU pulse labeling followed by FACs 
analysis. Lastly, to determine the effect of survivin expression on docetaxel 
binding to microtubules, FACs and IF would be utilized, making use of a 
fluorescent paclitaxel derivative Flutax-2 as a probe. It is possible that survivin 
may block or interfere with docetaxel’s binding to microtubules and therefore 
contribute to its ineffectiveness and cells resistance to treatment. The above 
series of experiments would provide a solid beginning for trying to specifically 
elucidate the cellular mechanism of survivin in docetaxel resistant prostate 
cancers. 
Lastly, considerable time should be spent to develop improved models for 
evaluating the therapeutic potential of the survivin inhibitors in vivo. For this the 
use of syngeneic prostate cancer mouse model should be implored. Both LQZ-7-
3 and LQZ-7F-1 should undergo formulation optimization for administration in the 
mice. In many of the previous studies the focus of analogue iterative generations 
involved improving potency in cell based assays as well as interaction with the 
survivin dimer. As I continue to develop these inhibitors, it is important to match 
the improvement in potency with an improved pharmacokinetic profile as well. In 
our future in vivo work pre-clinical pharmacokinetic assays will be critical to build 
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the portfolio for these compounds. An improvement in potency or binding affinity 
to survivin becomes meaningless if these compounds are metabolized to an 
inactive form or excreted from the body too quickly. Careful study and 
consideration must be a priority going forward to demonstrate a viable 
pharmacokinetic profile for each compound. Going forward each compound 
should be further evaluated in efficacies studies using syngeneic models as a 
single agent and in particular a combination therapy with docetaxel. These 
studies would help the pursuit to translate these compounds into a viable anti-
cancer treatment option down the road for patients. 
 
6.4 Meaning of Work 
The development of resistance to docetaxel and inevitability of metastasis 
in castration resistant prostate cancer patients represents a significant hurdle to a 
successful clinical outcome as the disease remains incurable. As stated above, 
survivin expression has been associated with biologically and clinically 
aggressive disease and poor patient outcome. The understanding that survivin is 
likely a large contributor to the resistant phenotype provides strong rationale that 
targeting survivin may improve patient outcomes and sensitize resistant patients 
to docetaxel. The long-term goals of this work are and continue to be to 
understand how survivin contributes to chemotherapy resistance and to use the 
direct survivin small molecule inhibitors to  sensitize tumors to docetaxel. The 
knowledge gained from the use of direct survivin inhibitors in our first 
translational studies has helped to identify potential lead candidates for clinical 
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development of inhibitors capable of sensitizing resistant prostate cancer cells to 
docetaxel. Previous clinical trials with agents designed to manipulate survivin 
expression have focused on targeting upstream transcription factors or utilizing 
antisense oligonucleotides and have experienced modest success and often 
times dose limiting side effects. By directly targeting survivin protein itself, it may 
be possible to overcome the problems that these other approaches have faced in 
clinical trials and prove to be a more appropriate option for treatment of CRPC. 
Finally, almost every solid tumor has been shown to overexpress survivin, 
therefore the work in this study to develop these survivin inhibitors may not be 
limited to prostate cancer setting and these inhibitors may have relevance in 
therapies for other cancer types. Hopefully, the knowledge from this study can 
eventually help accomplish the ultimate goal of translating this work help cure 
patients. 
 
6.5 PhD Experience  
 The PhD experience while often times extremely frustrating and 
challenging, has in the end been a truly rewarding experience. I came to 
graduate school to further my scientific knowledge and skills to make myself 
more marketable in the job market. I believe my passion for science went beyond 
the undergraduate level. As an undergraduate in the academic and industry 
settings I was comfortable reading and for the most part understanding scientific 
literature. However, journal clubs became difficult when thought provoking 
questions were asked that required more critical thinking of each experiment and 
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detail . I think the biggest leap and change I have seen through my graduate 
studies, is that my mentor, faculty members, and peers have really challenged 
and helped me excel at critical thinking. The ability to evaluate, ask challenging 
questions, and critique my work and the work of others is a tremendous skill I 
have gained in graduate school. I think the growth in looking at a scientific 
protocol and being able to distinguish why each step is performed is another 
tremendous skill graduate school has taught me. I also leave graduate school 
much more confident in scientific presentations whether it be seminars or poster 
sessions. Overall, there is not much I would change about my graduate 
experience. I do think if I could go back I would look to establish more 
collaborations during my project to expose myself to even more scientific 
techniques and gain knowledge from experts in their field. I would also start my in 
vivo work much earlier in the graduate process as I many times at poster 
sessions or seminars I was told that was the one area missing from my data that 
held me back from winning awards at conferences. In the end I am truly grateful 
for the experiences I have had at IUSM that have shaped the scientist I have 
become and believe the skills I have learned along the way will allow me to 
succeed in future endeavors.  
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